DermaFix Nail Fungus Treatment Gel Claims Evaluated in 2026 Market Report Covering Tea Tree Oil Research, Penetration Technology Positioning, and Pricing Transparency




DermaFix Nail Fungus Treatment Gel Claims Evaluated in 2026 Market Report Covering Tea Tree Oil Research, Penetration Technology Positioning, and Pricing Transparency

An informational industry analysis examining ingredient-level research, marketing positioning trends, regulatory context, and publicly listed pricing structures in the topical nail fungus category

Sheridan, WY, March 03, 2026 (GLOBE NEWSWIRE) — This article contains affiliate links. If a purchase is made through these links, a commission may be earned at no additional cost to the buyer. This article is an informational overview and does not constitute medical, health, or dermatological advice. All product details described below are stated as presented by the company and should be verified directly on the official website before any purchasing decision.

This release provides informational analysis of publicly available product and ingredient data and does not constitute a product review or endorsement.

Consumer interest in topical nail fungus treatment alternatives continues to grow in 2026. Search volume for ingredient-based antifungal formulations has increased as more adults explore options beyond prescription oral antifungals — medications that work systemically but carry well-documented side effect profiles including liver function concerns and required blood monitoring.

If you have been researching topical nail fungus treatments online, you have likely encountered products built around tea tree oil, colloidal silver, and penetration-enhancing carrier oils. DermaFix Nail Fungus Treatment Gel is one example currently marketed in this category. With that visibility come real questions: Are the formula’s core ingredients supported by published research for nail fungus applications? Does the gel’s delivery system address the well-documented challenge of penetrating the nail plate? And how do those claims align with published research and typical transparency standards within the topical antifungal category?

This report evaluates what the company states, what ingredient-level research supports under controlled study conditions, and where gaps remain between marketing language and product-level clinical evidence.

Current product details, pricing, and terms can be confirmed by viewing the current DermaFix offer (official DermaFix page).

Individual results vary. Topical nail care products are not substitutes for professional dermatological evaluation or prescription antifungal treatment. Consult a qualified healthcare provider before starting any new topical regimen for nail concerns.

2026 Topical Nail Fungus Market Context

Onychomycosis — the clinical term for fungal nail infection — is one of the most common nail disorders worldwide. A 2024 global prevalence review published in the journal Mycoses reported that dermatophyte-caused toenail infections affect approximately 4% of the general population, with prevalence increasing substantially with age, diabetes, and other comorbidities. The condition is recognized in dermatological literature as notoriously difficult to treat, even with FDA-approved therapies.

This difficulty has created sustained consumer demand for alternative and complementary topical approaches. Products positioned around naturally-derived ingredients — particularly tea tree oil, which has a longer research history than most botanical antifungals — have gained increased visibility in direct-to-consumer channels. The category is characterized by several recurring trends worth understanding before evaluating any individual product.

Ingredient transparency varies widely. Some brands disclose exact concentrations per ingredient. Others, including many gel and oil-based formulations, list ingredients without specifying individual amounts — making it difficult for consumers or healthcare providers to compare formulations against published research dosages.

The penetration challenge remains central. The nail plate is composed of densely packed layers of hard keratin that create a formidable barrier to most topical agents. Published dermatology reviews consistently identify nail penetration as one of the primary obstacles in topical onychomycosis treatment. Many products in this category market “deep penetration” claims — the evidence supporting those claims varies significantly from product to product.

Regulatory classification matters. Products marketed as cosmetics or personal care items face different regulatory requirements than products marketed as drugs. The distinction affects what claims a company can legally make and what level of clinical evidence is required to support those claims.

What DermaFix Is and How It Is Positioned

DermaFix Nail Fungus Treatment Gel is a topical gel positioned as a naturally-derived alternative to prescription antifungals and standard topical creams. The product is distributed by Aura Health LLC out of Sheridan, Wyoming, with the website operated by Haur B.V. (Netherlands). The product seller is listed as STR.VERT Consultants Ltd (Cyprus).

The formula combines six ingredients: Tea Tree Oil, Colloidal Silver, Emu Oil, Vitamin E, Bacillus Ferment, and Squalane. Each tube contains 20 ml (0.68 oz). Marketing describes the formula as “nature inspired, clinically tested,” though specific clinical testing documentation — including published study citations, trial registrations, or peer-reviewed publication links — is not provided on the product website.

The website states DermaFix targets the nail bed beneath the nail plate where fungal infections colonize. Individual ingredient concentrations are not disclosed on the label or website, which limits comparison against dosages used in published research.

Tea Tree Oil Research: What Published Evidence Shows

Tea tree oil is the ingredient most prominently associated with DermaFix’s antifungal positioning. It also happens to be the ingredient with the most published research relevant to nail fungus — which makes it the right place to start when evaluating the evidence landscape.

A 1994 randomized controlled trial published in the Journal of Family Practice compared 100% tea tree oil to 1% clotrimazole solution in 117 patients over six months. Both treatments showed comparable clinical improvement, though neither achieved high rates of full mycological cure. A separate 1999 placebo-controlled study tested a cream containing 5% tea tree oil combined with 2% butenafine hydrochloride, achieving an 80% cure rate — though tea tree oil alone did not produce full cures in that trial.

More recent laboratory research has confirmed tea tree oil’s fungistatic effects against the dermatophytes most commonly responsible for nail infections, including Trichophyton rubrum and Trichophyton mentagrophytes — the organisms behind the vast majority of onychomycosis cases.

Here is what that research means in practical terms. Tea tree oil has demonstrated measurable antifungal activity in both clinical and laboratory settings. That is a real finding on a real compound. But the studies tested either pure tea tree oil at 100% concentration or standardized preparations at known dosages. DermaFix lists tea tree oil as one of six ingredients without disclosing its concentration. Whether the amount in DermaFix reaches levels associated with antifungal activity in published research cannot be confirmed from the label alone.

Additionally, antifungal activity demonstrated in a laboratory setting does not automatically translate to clinical effectiveness when applied to an infected nail. The nail plate’s keratin barrier is a fundamentally different challenge than a petri dish — and this penetration gap is exactly why topical nail fungus treatment remains so difficult across the entire category, not just for DermaFix.

Penetration Technology Claims: What the Category Promises vs. What Research Supports

DermaFix markets a “penetrating oil-based formula” as its primary differentiator. The website states that most treatments fail because “they never reach where the fungus actually lives” and that DermaFix “solves the penetration problem” using emu oil and squalane as deep-penetration carriers.

Emu oil has published research supporting its skin penetration-enhancing properties. Some studies suggest it may facilitate transdermal delivery of certain compounds through the skin. However, skin penetration and nail plate penetration involve different biological barriers with different structural properties. Published research specifically examining emu oil’s ability to deliver active compounds through the hard keratin of the nail plate is limited.

The marketing claim that emu oil carries active ingredients “through the nail plate within minutes” represents the company’s promotional positioning rather than a finding documented in published nail-specific penetration research. This distinction is worth understanding — not because the claim is necessarily wrong, but because it has not been independently verified through published study.

Performance Statistics and Marketing Claims on the DermaFix Website

The DermaFix website presents several specific performance statistics, including claims that 93% of users eliminated fungal infection within 8-12 weeks, 95% experienced no reinfection, and 90% noticed improvement within the first two weeks. Elsewhere on the site, slightly different figures appear: 94% said nail fungus was eliminated and 86% experienced less foot odor.

The methodology behind these statistics — including study design, sample size, measurement standards, and whether an independent third party conducted or verified the research — is not disclosed on the website. A quote attributed to “Dr. Emily Rowan, MD, Dermatology & Nail Health Specialist” appears on the product page, but verifiable credentials and institutional affiliation are not provided.

The company’s own footer disclaimer states that “Health Claims on the website have not been proved scientifically or evaluated by doctors.” These disclosures are worth reading carefully before relying on any statistical or testimonial claims to form expectations about the product.

For context, even FDA-approved topical antifungals — which have been evaluated through randomized, placebo-controlled clinical trials — report relatively modest complete cure rates. Published dermatological literature indicates toenail fungus treatment typically requires 12 to 18 months for a complete toenail to grow out, and even prescription topical treatments require 48-week treatment periods in clinical trials. Any topical product claiming visible results in two to four weeks should be evaluated against this well-established clinical timeline.

Colloidal Silver in the Topical Antifungal Category

DermaFix includes colloidal silver as a primary ingredient, described on its website as having antimicrobial properties. Silver compounds have demonstrated antifungal activity in published laboratory research. However, clinical evidence specifically supporting colloidal silver as a topical treatment for nail fungus is limited.

The FDA issued a final rule in 1999 determining that over-the-counter drug products containing colloidal silver ingredients are not generally recognized as safe and effective. DermaFix appears to be marketed as a topical personal care product rather than an FDA-approved drug. The website’s own footer disclaimer acknowledges that health claims have not been scientifically proved. This regulatory context is worth factoring into any product evaluation in this category.

DermaFix Pricing and Purchase Structure

According to pricing published on the official website at the time of this report:

Single Tube: $29.97 per tube.

Buy 1, Get 1 50% Off (2 Tubes): $22.49 per tube.

Buy 2, Get 2 Free (4 Tubes): $14.99 per tube.

The website describes free shipping and a 90-day money-back guarantee across all options. Consumers can confirm current pricing and availability by viewing the current DermaFix offer (official DermaFix page), as pricing may change at any time.

DermaFix Refund Policy

The company’s published Terms and Conditions describe a 90-day money-back guarantee with specific conditions that are worth reviewing carefully. Returned products must be unopened, in original packaging, and in resalable condition to be eligible for a refund. Opened or used tubes are described as non-refundable.

Return shipping is the buyer’s responsibility, and the company does not provide pre-paid return labels. The published processing timeline is seven to fourteen business days for inspection after receipt, followed by five to twenty business days for the refund to appear depending on the payment method and financial institution.

Where DermaFix Fits Within the 2026 Topical Nail Care Category

Based on its positioning and ingredient profile, DermaFix occupies a specific niche within the broader topical nail fungus market: naturally-derived, non-prescription, multi-ingredient formulations that emphasize penetration-enhancing carrier systems over pharmaceutical-grade active ingredients.

This positioning reflects a segment of the market focused on botanical-based topical formulations and non-prescription alternatives. It may be less aligned with consumers who require transparent ingredient concentrations, those dealing with severe infections that may require prescription treatment, or individuals expecting clinical-level cure rates from a single topical product.

As with any product in this category, a dermatologist or podiatrist can confirm whether a nail condition is actually caused by a fungal infection — not all nail discoloration or thickening is fungal in origin — and recommend the most appropriate evidence-based treatment approach for the specific situation.

Transparency Standards Typically Expected in This Category

Ingredient concentration disclosure. Products that list individual concentrations allow consumers and healthcare providers to compare against published research dosages. DermaFix does not disclose individual concentrations.

Clinical evidence documentation. The phrase “clinically tested” carries more weight when accompanied by published study citations, trial registration numbers, or peer-reviewed publication links. These are not provided on the DermaFix website.

Refund policy clarity. The 90-day guarantee applies only to unopened products. This is a meaningful distinction from guarantee language that implies risk-free trial usage.

Corporate structure transparency. Three entities across three countries are involved in the DermaFix transaction. The platform operator states it does not manufacture, test, or store the products.

Professional consultation. Any topical nail care regimen should ideally begin with a confirmed diagnosis from a qualified healthcare provider.

Frequently Asked Questions About Topical Nail Fungus Products and Ingredient Research

Is DermaFix an FDA-approved antifungal drug?

DermaFix does not appear to be marketed as an FDA-approved drug product. A disclaimer on the website states that health claims have not been scientifically proved or evaluated by doctors.

Does DermaFix disclose tea tree oil concentration?

Tea tree oil is listed as one of six primary ingredients, but its concentration is not disclosed. Published clinical research has tested tea tree oil at concentrations ranging from 5% to 100%.

What is the published evidence for colloidal silver in nail fungus treatment?

Silver compounds have demonstrated antimicrobial properties in laboratory settings. Published clinical evidence specifically supporting colloidal silver for nail fungus is limited. The FDA has stated that colloidal silver products marketed for therapeutic purposes are not generally recognized as safe and effective.

Can emu oil penetrate the nail plate?

Emu oil has published research supporting skin penetration enhancement. The nail plate presents a structurally different and more resistant barrier than skin. Published nail-specific penetration data for emu oil is limited.

What does “clinically tested” mean on the DermaFix website?

This phrase appears prominently but is not accompanied by published study citations, trial registration numbers, or links to peer-reviewed journals.

How does the 90-day guarantee work?

Per the published Terms and Conditions, refund eligibility requires products to be returned unopened, in original packaging, and in resalable condition. The buyer is responsible for return shipping costs.

How long does nail fungus treatment typically take?

Published dermatological literature indicates toenail fungus treatment typically requires 12 to 18 months for a complete toenail to grow out. Even FDA-approved topical antifungals require 48-week treatment periods in clinical trials.

Should I see a doctor before using a topical nail fungus product?

Yes. A dermatologist or podiatrist can confirm whether a nail condition is actually fungal in origin, identify the specific organism, and recommend evidence-based treatment. Not all nail discoloration or thickening is caused by fungus.

How do FDA-approved topical antifungals compare to non-prescription alternatives?

FDA-approved topical antifungals have been evaluated through randomized, placebo-controlled clinical trials with published efficacy data. Non-prescription topical products in this category generally have not undergone comparable evaluation as finished formulations.

Additional Independent Research

Independent research across peer-reviewed dermatology journals and clinical resources may provide broader perspective on topical nail fungus treatments, tea tree oil research, and antifungal product evaluation standards. Evaluating multiple sources is recommended before making any purchasing decision. Consumers may also wish to review the FDA’s guidance on cosmetic and drug product classifications and the American Academy of Dermatology’s patient resources on nail fungus treatment.

Summary of Key Findings

DermaFix Nail Fungus Treatment Gel is positioned within the growing category of naturally-derived topical nail care formulations. Tea tree oil, its most prominently marketed ingredient, has published peer-reviewed research demonstrating antifungal activity at the individual compound level. However, individual ingredient concentrations are not disclosed, and no published clinical trial has evaluated the finished product as formulated.

The 90-day refund guarantee requires unopened products for eligibility. Performance statistics and testimonials are presented alongside a disclaimer stating that health claims have not been scientifically proved. The multi-entity corporate structure spanning the Netherlands, Cyprus, and Wyoming is a factor worth considering.

Complete product details, current pricing, and published terms are available by viewing the current DermaFix offer (official DermaFix page).

About the Companies Listed in This Report

Aura Health LLC is a limited liability company organized under the laws of the State of Wyoming, USA, with a registered address at 30 N Gould St, STE R, Sheridan, WY 82801. The company is listed as the U.S. contact entity for the DermaFix product.

Haur B.V. is a private limited company incorporated under the laws of the Netherlands, registered with the Netherlands Chamber of Commerce (RSIN: 867612939), with a company address at John M. Keynesplein 1, 1066EP Amsterdam. Haur B.V. operates the DermaFix website as the platform operator.

STR.VERT Consultants Ltd (company code: HE467408) is registered in Cyprus at Lapithou 11, Flat/Office 101, Egkomi 2410, Lefkosia. STR.VERT is listed as the product seller responsible for product organization and delivery.

Contact Information

Email: hello@trydermafix.com

Phone: +1 (484) 263-5085

Website: https://trydermafix.com

Disclaimers

Content and Information Disclaimer: This article is an independent informational overview and does not constitute medical, health, dermatological, or legal advice. This release provides informational analysis of publicly available product and ingredient data and does not constitute a product review or endorsement. All product details, ingredient information, pricing, and policy terms described in this article are stated as presented by the company on its publicly available website and product labeling. This content has not been independently audited or verified unless specifically noted.

Health and Dermatological Notice: Nail discoloration, thickening, and brittleness can have multiple causes including fungal infection, psoriasis, and trauma. Professional diagnosis is recommended before self-treating any nail condition. The statements made by the manufacturer regarding this product have not been evaluated by the Food and Drug Administration. Individual results vary based on numerous factors. Nail health concerns should be discussed with a qualified dermatologist or podiatrist.

Results, Pricing, and Product Variability: All pricing, shipping terms, and refund policies referenced in this article are based on information published on the official product website at the time of writing and may change without notice. Consumers should verify current terms through the official website before completing any purchase.

FTC Affiliate Disclosure and Publisher Responsibility: This article contains affiliate links. If a product is purchased through these links, a commission may be earned at no additional cost to the buyer. The publisher is not responsible for typographical errors, manufacturer changes after publication, or individual consumer outcomes. The seller’s role does not constitute an endorsement, approval, or review of any claims made in the promotion of this product.

CONTACT: Email: hello@trydermafix.com
Phone: +1 (484) 263-5085

MemoTril Cognitive Support Claims Evaluated: Latest 2026 Consumer Report Examines MemoTril Brain Supplement Ingredients, Memory Enhancement Marketing, and What Consumers Should Verify




MemoTril Cognitive Support Claims Evaluated: Latest 2026 Consumer Report Examines MemoTril Brain Supplement Ingredients, Memory Enhancement Marketing, and What Consumers Should Verify

Informational 2026 consumer report examining MemoTril brain supplement ingredients, cognitive support marketing claims, ingredient research context, pricing disclosures, and what consumers should verify before purchasing

Plano, TX, March 03, 2026 (GLOBE NEWSWIRE) — This article contains affiliate links. If a purchase is made through these links, a commission may be earned at no additional cost to the buyer. This article is an informational overview and does not constitute medical, health, or dietary advice. All product details described below are stated as presented by the company and should be verified directly on the official website before any purchasing decision.

This report does not evaluate MemoTril as a product recommendation and does not endorse or discourage its use. The purpose is to examine publicly available information about the product and its ingredients.

Consumer interest in brain health supplements has continued to expand heading into 2026. Adults across a broad age range are increasingly researching dietary approaches to supporting memory, focus, and mental clarity — particularly as awareness of age-related cognitive changes becomes a more visible topic in mainstream health media.

Search activity for terms such as “natural cognitive support,” “brain fog supplement,” “memory enhancement formula,” and “nootropic ingredients” has risen significantly in recent years. This reflects a broader shift toward proactive wellness, with consumers increasingly seeking clarity on what published research does and does not support before making purchasing decisions.

MemoTril is one of the products that has appeared prominently in these searches. Marketed as a natural brain health supplement designed to support memory, focus, and mental clarity, MemoTril has generated consumer questions about its ingredient profile, the research behind its listed compounds, and how its marketing language should be interpreted relative to published scientific evidence.

This report examines what the company states about MemoTril, what ingredient-level research supports under controlled study conditions, and where gaps remain between marketing language and product-level clinical evidence. Current product details, pricing, and terms can be confirmed by viewing the current MemoTril offer (official MemoTril page).

Individual results vary. Dietary supplements are not substitutes for balanced nutrition, regular physical activity, or professional medical guidance. Consult a qualified healthcare provider before starting any new supplement regimen.

Consumer Interest in Cognitive Support Supplements Continues Rising

The cognitive support supplement category has experienced sustained growth over the past several years. The global brain health supplement market has expanded as aging populations and increased interest in cognitive wellness drive consumer demand for products positioned around memory, focus, and mental performance.

Search interest for terms such as “brain health supplement,” “memory support capsules,” and “natural nootropic ingredients” has increased significantly as consumers explore dietary approaches to supporting cognitive wellness. This growth has been accompanied by heightened consumer scrutiny around ingredient transparency, dosage disclosure, and the distinction between marketing language and published clinical evidence.

Within this landscape, products marketed as natural brain supplements have attracted attention from adults who describe experiencing brain fog, declining recall, or reduced concentration — particularly after age 35. Consumer search behavior in this category suggests that buyers are increasingly looking beyond marketing promises and seeking verifiable ingredient research before committing to a purchase.

Understanding the Regulation of Dietary Supplements

Dietary supplements such as MemoTril are regulated differently from pharmaceutical drugs in the United States. Under the Dietary Supplement Health and Education Act (DSHEA), supplement manufacturers are responsible for ensuring product safety and accurate labeling. The U.S. Food and Drug Administration does not approve dietary supplements for safety or effectiveness before they reach the market.

This regulatory framework means that the claims made on a supplement’s product page or marketing materials have not been pre-evaluated by a federal agency for accuracy. Consumers researching any cognitive support supplement should understand that the standard of evidence for dietary supplement marketing differs substantially from the clinical trial requirements applied to prescription medications.

What Is MemoTril

MemoTril is a dietary supplement marketed as a natural cognitive support formula designed to support memory, focus, and mental clarity. The company sells it as a daily capsule and positions it as a plant-based approach to brain health. According to the official website, the product is distributed by MemoTril Research and sold exclusively through its direct-to-consumer online storefront, with payments processed through CartPanda Inc. as the authorized retailer.

The company’s published product information states that MemoTril is manufactured in the United States in an FDA-registered facility that follows Good Manufacturing Practices (GMP). The website describes the supplement as containing 100% natural ingredients. The company markets the product toward adults experiencing brain fog, forgetfulness, and mental fatigue.

Per the official product page, the formula targets five areas as described by the company: memory recall, mental clarity, focus and concentration, mental energy, and long-term brain health support. Six primary ingredients are listed: Bacopa Monnieri, Lion’s Mane Mushroom, Ginkgo Biloba, Phosphatidylserine, Rhodiola Rosea, and Omega-3 DHA.

Individual ingredient amounts per capsule are not disclosed on the publicly available product page. The specific dosage of each compound within the formula has not been published in the materials reviewed for this report.

MemoTril Ingredient Profile: What the Company Discloses

Consumers evaluating brain health supplements often examine ingredient transparency, dosage disclosure, and supporting research for each compound included in a formula. The MemoTril product page lists six primary ingredients. Several have published peer-reviewed research behind them at the individual compound level.

Published research examining individual ingredients such as Bacopa monnieri and phosphatidylserine has explored their potential roles in memory, attention, and cognitive performance. It is important to note that these studies evaluate individual ingredients rather than the MemoTril formulation itself. All ingredient research referenced in this report reflects studies conducted on isolated compounds, not clinical trials evaluating MemoTril as a finished proprietary formula.

Bacopa Monnieri is one of the most studied botanical nootropics. A 2014 meta-analysis in the Journal of Ethnopharmacology examining nine randomized controlled trials with 518 subjects found that standardized Bacopa extract showed potential to improve cognition, particularly speed of attention. Clinical trials have typically used 300 to 450 mg of standardized extract daily over at least 12 weeks.

Lion’s Mane Mushroom (Hericium erinaceus) has preclinical research supporting its role in nerve growth factor production. A small 2009 trial in Phytotherapy Research observed cognitive improvements in 30 older adults after 16 weeks of supplementation.

Ginkgo Biloba has been examined in multiple clinical reviews. Studies have typically used around 240 mg per day of standardized EGb 761 extract, with clinical reviews noting potential support for cognitive function in specific populations during extended use.

Phosphatidylserine has been studied at dosages of 100 to 300 mg daily. Some regulatory discussions around phosphatidylserine have referenced the possibility that the ingredient may support cognitive function in aging populations, though evidence remains limited and applies to the ingredient rather than the MemoTril formulation.

Rhodiola Rosea is an adaptogenic herb studied for its effects on stress response and mental performance under fatigue.

Omega-3 DHA is a major structural component of brain tissue. Large-scale observational studies have associated higher omega-3 intake with cognitive health, though supplementation trials in healthy adults have produced mixed results.

Here is the critical consideration for anyone evaluating this formula: MemoTril does not appear to publicly disclose individual ingredient dosages on its product page. Without knowing how much of each compound is present per serving, consumers cannot directly compare the formula against the specific dosages used in published clinical research.

MemoTril Marketing Claims Examined

The central marketing narrative positions MemoTril as a formula that can help adults “restore mental clarity and reclaim their sharp memory.” The company describes the formula as containing “scientifically-proven ingredients” and states that the product has been used by thousands of customers.

Several of the individual ingredients listed in MemoTril do have published peer-reviewed research supporting their potential to influence aspects of cognitive function. Bacopa monnieri and phosphatidylserine, in particular, have been examined across multiple randomized controlled trials. That said, important distinctions exist between ingredient-level evidence and product-level claims.

Published studies that form the evidence base for these ingredients tested isolated compounds at known, disclosed dosages under controlled research conditions. Bacopa monnieri trials typically used 300 to 450 mg of standardized extract daily over at least 12 weeks. Phosphatidylserine research has generally examined 100 to 300 mg daily. Ginkgo biloba studies commonly used 240 mg per day of standardized extract.

Individual ingredient amounts in MemoTril are not disclosed on the publicly available product page. Without this information, consumers cannot determine whether any single ingredient is present at the dosages published research has examined. The phrase “scientifically-proven ingredients” on the company’s website references the research status of individual compounds, not a clinical evaluation of MemoTril as a finished multi-ingredient formulation.

Consumers researching terms such as “MemoTril effectiveness,” “does MemoTril work,” “MemoTril brain health results,” or “MemoTril cognitive enhancement” should understand that marketing claims referencing scientific research describe ingredient-level findings, not product-level clinical outcomes verified through independent testing of the finished supplement.

What Would Be Required to Demonstrate Product-Level Effectiveness

For a dietary supplement to demonstrate effectiveness through clinical evidence, the standard generally includes a randomized, placebo-controlled trial using the finished product at its actual dosage. Such a study would need to disclose the exact formulation, specify duration of use, define measurable endpoints — such as changes in memory recall scores or cognitive processing speed — and enroll a study population that represents the product’s target consumer. Results would typically be published in a peer-reviewed journal and subject to independent scrutiny.

While individual ingredients included in cognitive supplements have been the subject of scientific studies, determining the effectiveness of a proprietary combination typically requires controlled clinical trials evaluating the finished formula. No publicly available clinical trial appears to have evaluated MemoTril as a finished proprietary formulation.

This distinction is not about dismissing MemoTril or any similar product. It is about clarifying the difference between ingredient-level research and product-level proof so consumers can make purchasing decisions based on the actual evidence landscape.

MemoTril Pricing and Availability

According to the official MemoTril website at the time of this report, the product is offered in several multi-bottle supply configurations that vary in price per bottle depending on the package selected. The company indicates that larger supply packages are frequently selected by customers. All purchases are described as one-time payments with no automatic rebilling.

For orders placed outside the United States, the company lists a fixed international shipping fee. Pricing, availability, and shipping terms may change, so consumers should verify current terms. Consumers can confirm current pricing and availability by viewing the current MemoTril offer (official MemoTril page), as pricing may change at any time.

MemoTril Refund Policy and Guarantee

The company states on its website that purchases may be covered by a 60-day refund policy. Consumers who wish to request a refund are instructed to contact the company’s customer support team.

The payment processor for MemoTril is CartPanda Inc., which maintains its own refund and return policy. CartPanda’s published terms provide a 30-day money-back guarantee for physical products as the platform standard, though individual sellers may offer extended refund periods. It is worth reviewing the specific terms on both the MemoTril product page and CartPanda’s published policies to confirm which guarantee applies.

Refund timelines depend on the buyer’s payment method and financial institution. CartPanda’s policy notes that refunds may take one to two billing cycles to appear on a credit card statement. Consumers should retain all purchase confirmation details and review the complete refund policy before ordering.

MemoTril Testimonials Context

Customer testimonials displayed on the official website describe individual experiences with focus, clarity, and memory recall. The site presents a 4.9-star average customer rating and uses marketing language stating that the formula has been used by thousands of customers.

These statements reflect promotional content and should not be interpreted as clinical evidence or typical outcomes. The bottom of the product page includes a standard FDA disclaimer confirming that the product’s claims have not been evaluated by the Food and Drug Administration. The page also discloses that “some names and personal identifying information on this site have been changed to protect the privacy of individuals.”

When a product website discloses that personal identifying details have been altered, that context is worth considering when evaluating testimonial-based claims presented on the site.

Consumer Verification Checklist

Verify individual ingredient dosages. Full-disclosure labeling allows consumers and healthcare providers to compare dosages against published research. If exact amounts are not available on the product page, consider contacting the manufacturer directly.

Separate ingredient research from product research. Many supplements reference published studies on individual compounds. Fewer have been tested as finished formulations through independent trials. Understanding this distinction helps set realistic expectations.

Read all disclosures on the product page carefully. The fine print often contains important context about whether results are typical, whether identifying details have been changed, and what the FDA disclaimer means for the product’s claims.

Confirm refund terms independently. Review guarantee terms, return requirements, and processing timelines directly on the official website and through the payment processor before purchasing.

Talk to your healthcare provider. This is especially important for adults taking prescription medications, managing chronic conditions, or experiencing cognitive changes that may warrant medical evaluation. Professional medical guidance should come before any supplement purchase.

Who the Product Appears to Be Marketed Toward

Based on the product’s positioning on its official website, MemoTril appears to be marketed toward adults exploring dietary supplements intended to support cognitive wellness. The company’s messaging emphasizes memory recall, mental clarity, focus, and brain health — with particular emphasis on adults who describe experiencing brain fog or age-related cognitive changes.

Some consumers researching supplements may prefer formulas that disclose individual ingredient dosing in order to compare them with published research. Others may prioritize products backed by clinical trials conducted on the finished formulation rather than individual ingredient studies. Consumers experiencing persistent cognitive symptoms may also wish to explore medical evaluation before considering any dietary supplement.

Supplements are regulated differently from pharmaceutical drugs. The FDA does not evaluate dietary supplement claims for efficacy before products reach the market. The FDA disclaimer on MemoTril’s own product page confirms that the product’s statements have not been evaluated by the Food and Drug Administration and that the product is not intended to diagnose, treat, cure, or prevent any disease.

Consumer Questions About MemoTril

What is MemoTril?

Positioned as a natural cognitive support formula, MemoTril contains six primary ingredients: Bacopa Monnieri, Lion’s Mane Mushroom, Ginkgo Biloba, Phosphatidylserine, Rhodiola Rosea, and Omega-3 DHA. The supplement is sold exclusively through its official website.

Is MemoTril FDA approved?

As a dietary supplement, MemoTril does not require FDA approval under current federal regulations. The company states the product is manufactured in an FDA-registered, GMP-certified facility, which relates to manufacturing standards rather than product approval or endorsement.

Are MemoTril’s ingredients studied?

Several ingredients listed in MemoTril — particularly Bacopa monnieri, phosphatidylserine, and Ginkgo biloba — have been examined in published peer-reviewed research. These studies tested individual compounds at specific known dosages, not the MemoTril formula as a finished product. Individual ingredient amounts in MemoTril are not disclosed on the publicly available product page.

What timeline does the company describe for noticing changes?

Per the company’s FAQ section, many users notice improvements in focus and mental clarity within the first two to three weeks, with optimal results described after at least three months of consistent use. Published research on Bacopa monnieri has typically required a minimum of 12 weeks of daily supplementation to observe measurable effects in controlled study conditions.

Can MemoTril be taken with other supplements or medications?

The company’s FAQ section states that MemoTril can generally be used alongside other supplements but should not be combined with products containing similar cognitive-enhancing compounds. Some listed ingredients, particularly Ginkgo biloba, have published interactions with certain medications including blood thinners. Consumers taking prescription medications should consult a healthcare provider before adding any supplement.

Where is MemoTril sold?

The supplement is available exclusively through the official website, per the company’s stated distribution policy. All transactions are processed through CartPanda Inc.

What refund policy does the company describe?

A 60-day money-back guarantee is described on the official website. Refund requests can be initiated through the company’s customer support team or through CartPanda’s support channel at support@cartpanda.com. Processing timelines depend on payment method and financial institution.

Is MemoTril safe?

The company states the supplement is made with natural ingredients and manufactured in an FDA-registered, GMP-certified facility. Consulting a healthcare provider before starting is recommended. Individual ingredients are generally well-studied for safety at typical supplemental dosages, though gastrointestinal side effects have been reported with Bacopa monnieri in some clinical studies, and Ginkgo biloba has known medication interactions.

Are the testimonials on the MemoTril website verified?

A disclosure at the bottom of the official website states that “some names and personal identifying information on this site have been changed to protect the privacy of individuals.” The standard FDA supplement disclaimer also appears. These disclosures are worth reviewing before relying on testimonial content to form expectations about personal outcomes.

Additional Consumer Research

As interest in cognitive support supplements continues to grow, experts generally recommend that consumers review ingredient transparency, examine available research, and consult qualified healthcare professionals before beginning any new supplement routine.

Consumers researching MemoTril may benefit from reviewing previously published independent reporting on this product. A 2026 product disclosure update examining MemoTril ingredient transparency and consumer interest in brain health supplement options provides additional context on what the company has publicly disclosed about its formula. Wellness researcher Holly Herman has also published an independent analysis of MemoTril consumer reviews and complaints examining real buyer feedback, refund experiences, and common concerns reported across multiple platforms.

Independent research across multiple consumer publications and peer-reviewed sources may provide broader perspective on nootropic supplements, brain health compounds, and cognitive support products. Evaluating multiple sources is recommended before making any purchasing decision. Consumers may also wish to review the FDA’s general guidance on dietary supplement labeling and claims.

Summary of Key Considerations

This report does not rate MemoTril as a product and does not recommend it. The purpose has been to examine publicly available information about MemoTril’s ingredient profile, marketing claims, pricing, and consumer-relevant disclosures.

MemoTril is a dietary supplement positioned as a natural cognitive support formula containing six ingredients with varying degrees of published ingredient-level research behind them. The company’s marketing materials describe the formula using language including “scientifically-proven ingredients” and state that the product has been used by thousands of customers. However, individual ingredient dosages are not publicly disclosed on the product page, and no published clinical trial has evaluated the finished product as formulated.

The company describes a 60-day refund guarantee, one-time purchase pricing, and states that the product is manufactured under GMP standards in an FDA-registered facility. Testimonials on the website are accompanied by a disclosure that names and personal details may have been changed.

Consumers researching cognitive supplements often weigh several factors, including ingredient transparency, manufacturing standards, refund policies, and whether published research exists for the compounds included in a formula. Those who have completed their own research and wish to review the full product details can do so. Complete product details, current pricing, and published terms are available by viewing the current MemoTril offer (official MemoTril page).

Contact Information

Company: MemoTril Research (Brand Owner)

Website: memotril.shop

Email: wellness@supportcaps.com

Payment Processor: CartPanda Inc., 555 Republic Dr, Plano, Texas 75074

Payment Processor Support: support@cartpanda.com

Disclaimers

Content and Consumer Information Disclaimer: This article is an independent informational overview and does not constitute medical, health, dietary, financial, or legal advice. All product details, ingredient information, pricing, and policy terms described in this article are stated as presented by the company on its publicly available website and product labeling. This content has not been independently audited or verified unless specifically noted. Readers are encouraged to verify all claims directly with the manufacturer and to consult a qualified healthcare professional before beginning any dietary supplement.

Supplement and Health Notice: Dietary supplements are not intended to diagnose, treat, cure, or prevent any disease. The statements made by the manufacturer regarding this product have not been evaluated by the Food and Drug Administration. Individual results vary based on numerous factors including age, baseline health, dietary habits, activity level, and consistency of use. Cognitive health concerns should be discussed with a qualified healthcare provider who is familiar with the individual’s personal medical history.

Results, Pricing, and Product Variability: All pricing, shipping terms, and refund policies referenced in this article are based on information published on the official product website at the time of writing and may change without notice. Consumers should verify current terms through the official website or the authorized payment processor before completing any purchase.

FTC Affiliate Disclosure and Publisher Responsibility: This article contains affiliate links. If a product is purchased through these links, a commission may be earned at no additional cost to the buyer. CartPanda Inc. serves as the authorized payment processor for this product. CartPanda’s role as payment processor does not constitute an endorsement, approval, or review of this product or any claim, statement, or opinion used in its promotion. The publisher of this article is not responsible for typographical errors, manufacturer changes to the product after publication, or individual consumer outcomes.

CONTACT: Email: wellness@supportcaps.com

MemoTril Cognitive Support Claims Evaluated: Latest 2026 Consumer Report Examines MemoTril Brain Supplement Ingredients, Memory Enhancement Marketing, and What Consumers Should Verify




MemoTril Cognitive Support Claims Evaluated: Latest 2026 Consumer Report Examines MemoTril Brain Supplement Ingredients, Memory Enhancement Marketing, and What Consumers Should Verify

Informational 2026 consumer report examining MemoTril brain supplement ingredients, cognitive support marketing claims, ingredient research context, pricing disclosures, and what consumers should verify before purchasing

Plano, TX, March 03, 2026 (GLOBE NEWSWIRE) — This article contains affiliate links. If a purchase is made through these links, a commission may be earned at no additional cost to the buyer. This article is an informational overview and does not constitute medical, health, or dietary advice. All product details described below are stated as presented by the company and should be verified directly on the official website before any purchasing decision.

This report does not evaluate MemoTril as a product recommendation and does not endorse or discourage its use. The purpose is to examine publicly available information about the product and its ingredients.

Consumer interest in brain health supplements has continued to expand heading into 2026. Adults across a broad age range are increasingly researching dietary approaches to supporting memory, focus, and mental clarity — particularly as awareness of age-related cognitive changes becomes a more visible topic in mainstream health media.

Search activity for terms such as “natural cognitive support,” “brain fog supplement,” “memory enhancement formula,” and “nootropic ingredients” has risen significantly in recent years. This reflects a broader shift toward proactive wellness, with consumers increasingly seeking clarity on what published research does and does not support before making purchasing decisions.

MemoTril is one of the products that has appeared prominently in these searches. Marketed as a natural brain health supplement designed to support memory, focus, and mental clarity, MemoTril has generated consumer questions about its ingredient profile, the research behind its listed compounds, and how its marketing language should be interpreted relative to published scientific evidence.

This report examines what the company states about MemoTril, what ingredient-level research supports under controlled study conditions, and where gaps remain between marketing language and product-level clinical evidence. Current product details, pricing, and terms can be confirmed by viewing the current MemoTril offer (official MemoTril page).

Individual results vary. Dietary supplements are not substitutes for balanced nutrition, regular physical activity, or professional medical guidance. Consult a qualified healthcare provider before starting any new supplement regimen.

Consumer Interest in Cognitive Support Supplements Continues Rising

The cognitive support supplement category has experienced sustained growth over the past several years. The global brain health supplement market has expanded as aging populations and increased interest in cognitive wellness drive consumer demand for products positioned around memory, focus, and mental performance.

Search interest for terms such as “brain health supplement,” “memory support capsules,” and “natural nootropic ingredients” has increased significantly as consumers explore dietary approaches to supporting cognitive wellness. This growth has been accompanied by heightened consumer scrutiny around ingredient transparency, dosage disclosure, and the distinction between marketing language and published clinical evidence.

Within this landscape, products marketed as natural brain supplements have attracted attention from adults who describe experiencing brain fog, declining recall, or reduced concentration — particularly after age 35. Consumer search behavior in this category suggests that buyers are increasingly looking beyond marketing promises and seeking verifiable ingredient research before committing to a purchase.

Understanding the Regulation of Dietary Supplements

Dietary supplements such as MemoTril are regulated differently from pharmaceutical drugs in the United States. Under the Dietary Supplement Health and Education Act (DSHEA), supplement manufacturers are responsible for ensuring product safety and accurate labeling. The U.S. Food and Drug Administration does not approve dietary supplements for safety or effectiveness before they reach the market.

This regulatory framework means that the claims made on a supplement’s product page or marketing materials have not been pre-evaluated by a federal agency for accuracy. Consumers researching any cognitive support supplement should understand that the standard of evidence for dietary supplement marketing differs substantially from the clinical trial requirements applied to prescription medications.

What Is MemoTril

MemoTril is a dietary supplement marketed as a natural cognitive support formula designed to support memory, focus, and mental clarity. The company sells it as a daily capsule and positions it as a plant-based approach to brain health. According to the official website, the product is distributed by MemoTril Research and sold exclusively through its direct-to-consumer online storefront, with payments processed through CartPanda Inc. as the authorized retailer.

The company’s published product information states that MemoTril is manufactured in the United States in an FDA-registered facility that follows Good Manufacturing Practices (GMP). The website describes the supplement as containing 100% natural ingredients. The company markets the product toward adults experiencing brain fog, forgetfulness, and mental fatigue.

Per the official product page, the formula targets five areas as described by the company: memory recall, mental clarity, focus and concentration, mental energy, and long-term brain health support. Six primary ingredients are listed: Bacopa Monnieri, Lion’s Mane Mushroom, Ginkgo Biloba, Phosphatidylserine, Rhodiola Rosea, and Omega-3 DHA.

Individual ingredient amounts per capsule are not disclosed on the publicly available product page. The specific dosage of each compound within the formula has not been published in the materials reviewed for this report.

MemoTril Ingredient Profile: What the Company Discloses

Consumers evaluating brain health supplements often examine ingredient transparency, dosage disclosure, and supporting research for each compound included in a formula. The MemoTril product page lists six primary ingredients. Several have published peer-reviewed research behind them at the individual compound level.

Published research examining individual ingredients such as Bacopa monnieri and phosphatidylserine has explored their potential roles in memory, attention, and cognitive performance. It is important to note that these studies evaluate individual ingredients rather than the MemoTril formulation itself. All ingredient research referenced in this report reflects studies conducted on isolated compounds, not clinical trials evaluating MemoTril as a finished proprietary formula.

Bacopa Monnieri is one of the most studied botanical nootropics. A 2014 meta-analysis in the Journal of Ethnopharmacology examining nine randomized controlled trials with 518 subjects found that standardized Bacopa extract showed potential to improve cognition, particularly speed of attention. Clinical trials have typically used 300 to 450 mg of standardized extract daily over at least 12 weeks.

Lion’s Mane Mushroom (Hericium erinaceus) has preclinical research supporting its role in nerve growth factor production. A small 2009 trial in Phytotherapy Research observed cognitive improvements in 30 older adults after 16 weeks of supplementation.

Ginkgo Biloba has been examined in multiple clinical reviews. Studies have typically used around 240 mg per day of standardized EGb 761 extract, with clinical reviews noting potential support for cognitive function in specific populations during extended use.

Phosphatidylserine has been studied at dosages of 100 to 300 mg daily. Some regulatory discussions around phosphatidylserine have referenced the possibility that the ingredient may support cognitive function in aging populations, though evidence remains limited and applies to the ingredient rather than the MemoTril formulation.

Rhodiola Rosea is an adaptogenic herb studied for its effects on stress response and mental performance under fatigue.

Omega-3 DHA is a major structural component of brain tissue. Large-scale observational studies have associated higher omega-3 intake with cognitive health, though supplementation trials in healthy adults have produced mixed results.

Here is the critical consideration for anyone evaluating this formula: MemoTril does not appear to publicly disclose individual ingredient dosages on its product page. Without knowing how much of each compound is present per serving, consumers cannot directly compare the formula against the specific dosages used in published clinical research.

MemoTril Marketing Claims Examined

The central marketing narrative positions MemoTril as a formula that can help adults “restore mental clarity and reclaim their sharp memory.” The company describes the formula as containing “scientifically-proven ingredients” and states that the product has been used by thousands of customers.

Several of the individual ingredients listed in MemoTril do have published peer-reviewed research supporting their potential to influence aspects of cognitive function. Bacopa monnieri and phosphatidylserine, in particular, have been examined across multiple randomized controlled trials. That said, important distinctions exist between ingredient-level evidence and product-level claims.

Published studies that form the evidence base for these ingredients tested isolated compounds at known, disclosed dosages under controlled research conditions. Bacopa monnieri trials typically used 300 to 450 mg of standardized extract daily over at least 12 weeks. Phosphatidylserine research has generally examined 100 to 300 mg daily. Ginkgo biloba studies commonly used 240 mg per day of standardized extract.

Individual ingredient amounts in MemoTril are not disclosed on the publicly available product page. Without this information, consumers cannot determine whether any single ingredient is present at the dosages published research has examined. The phrase “scientifically-proven ingredients” on the company’s website references the research status of individual compounds, not a clinical evaluation of MemoTril as a finished multi-ingredient formulation.

Consumers researching terms such as “MemoTril effectiveness,” “does MemoTril work,” “MemoTril brain health results,” or “MemoTril cognitive enhancement” should understand that marketing claims referencing scientific research describe ingredient-level findings, not product-level clinical outcomes verified through independent testing of the finished supplement.

What Would Be Required to Demonstrate Product-Level Effectiveness

For a dietary supplement to demonstrate effectiveness through clinical evidence, the standard generally includes a randomized, placebo-controlled trial using the finished product at its actual dosage. Such a study would need to disclose the exact formulation, specify duration of use, define measurable endpoints — such as changes in memory recall scores or cognitive processing speed — and enroll a study population that represents the product’s target consumer. Results would typically be published in a peer-reviewed journal and subject to independent scrutiny.

While individual ingredients included in cognitive supplements have been the subject of scientific studies, determining the effectiveness of a proprietary combination typically requires controlled clinical trials evaluating the finished formula. No publicly available clinical trial appears to have evaluated MemoTril as a finished proprietary formulation.

This distinction is not about dismissing MemoTril or any similar product. It is about clarifying the difference between ingredient-level research and product-level proof so consumers can make purchasing decisions based on the actual evidence landscape.

MemoTril Pricing and Availability

According to the official MemoTril website at the time of this report, the product is offered in several multi-bottle supply configurations that vary in price per bottle depending on the package selected. The company indicates that larger supply packages are frequently selected by customers. All purchases are described as one-time payments with no automatic rebilling.

For orders placed outside the United States, the company lists a fixed international shipping fee. Pricing, availability, and shipping terms may change, so consumers should verify current terms. Consumers can confirm current pricing and availability by viewing the current MemoTril offer (official MemoTril page), as pricing may change at any time.

MemoTril Refund Policy and Guarantee

The company states on its website that purchases may be covered by a 60-day refund policy. Consumers who wish to request a refund are instructed to contact the company’s customer support team.

The payment processor for MemoTril is CartPanda Inc., which maintains its own refund and return policy. CartPanda’s published terms provide a 30-day money-back guarantee for physical products as the platform standard, though individual sellers may offer extended refund periods. It is worth reviewing the specific terms on both the MemoTril product page and CartPanda’s published policies to confirm which guarantee applies.

Refund timelines depend on the buyer’s payment method and financial institution. CartPanda’s policy notes that refunds may take one to two billing cycles to appear on a credit card statement. Consumers should retain all purchase confirmation details and review the complete refund policy before ordering.

MemoTril Testimonials Context

Customer testimonials displayed on the official website describe individual experiences with focus, clarity, and memory recall. The site presents a 4.9-star average customer rating and uses marketing language stating that the formula has been used by thousands of customers.

These statements reflect promotional content and should not be interpreted as clinical evidence or typical outcomes. The bottom of the product page includes a standard FDA disclaimer confirming that the product’s claims have not been evaluated by the Food and Drug Administration. The page also discloses that “some names and personal identifying information on this site have been changed to protect the privacy of individuals.”

When a product website discloses that personal identifying details have been altered, that context is worth considering when evaluating testimonial-based claims presented on the site.

Consumer Verification Checklist

Verify individual ingredient dosages. Full-disclosure labeling allows consumers and healthcare providers to compare dosages against published research. If exact amounts are not available on the product page, consider contacting the manufacturer directly.

Separate ingredient research from product research. Many supplements reference published studies on individual compounds. Fewer have been tested as finished formulations through independent trials. Understanding this distinction helps set realistic expectations.

Read all disclosures on the product page carefully. The fine print often contains important context about whether results are typical, whether identifying details have been changed, and what the FDA disclaimer means for the product’s claims.

Confirm refund terms independently. Review guarantee terms, return requirements, and processing timelines directly on the official website and through the payment processor before purchasing.

Talk to your healthcare provider. This is especially important for adults taking prescription medications, managing chronic conditions, or experiencing cognitive changes that may warrant medical evaluation. Professional medical guidance should come before any supplement purchase.

Who the Product Appears to Be Marketed Toward

Based on the product’s positioning on its official website, MemoTril appears to be marketed toward adults exploring dietary supplements intended to support cognitive wellness. The company’s messaging emphasizes memory recall, mental clarity, focus, and brain health — with particular emphasis on adults who describe experiencing brain fog or age-related cognitive changes.

Some consumers researching supplements may prefer formulas that disclose individual ingredient dosing in order to compare them with published research. Others may prioritize products backed by clinical trials conducted on the finished formulation rather than individual ingredient studies. Consumers experiencing persistent cognitive symptoms may also wish to explore medical evaluation before considering any dietary supplement.

Supplements are regulated differently from pharmaceutical drugs. The FDA does not evaluate dietary supplement claims for efficacy before products reach the market. The FDA disclaimer on MemoTril’s own product page confirms that the product’s statements have not been evaluated by the Food and Drug Administration and that the product is not intended to diagnose, treat, cure, or prevent any disease.

Consumer Questions About MemoTril

What is MemoTril?

Positioned as a natural cognitive support formula, MemoTril contains six primary ingredients: Bacopa Monnieri, Lion’s Mane Mushroom, Ginkgo Biloba, Phosphatidylserine, Rhodiola Rosea, and Omega-3 DHA. The supplement is sold exclusively through its official website.

Is MemoTril FDA approved?

As a dietary supplement, MemoTril does not require FDA approval under current federal regulations. The company states the product is manufactured in an FDA-registered, GMP-certified facility, which relates to manufacturing standards rather than product approval or endorsement.

Are MemoTril’s ingredients studied?

Several ingredients listed in MemoTril — particularly Bacopa monnieri, phosphatidylserine, and Ginkgo biloba — have been examined in published peer-reviewed research. These studies tested individual compounds at specific known dosages, not the MemoTril formula as a finished product. Individual ingredient amounts in MemoTril are not disclosed on the publicly available product page.

What timeline does the company describe for noticing changes?

Per the company’s FAQ section, many users notice improvements in focus and mental clarity within the first two to three weeks, with optimal results described after at least three months of consistent use. Published research on Bacopa monnieri has typically required a minimum of 12 weeks of daily supplementation to observe measurable effects in controlled study conditions.

Can MemoTril be taken with other supplements or medications?

The company’s FAQ section states that MemoTril can generally be used alongside other supplements but should not be combined with products containing similar cognitive-enhancing compounds. Some listed ingredients, particularly Ginkgo biloba, have published interactions with certain medications including blood thinners. Consumers taking prescription medications should consult a healthcare provider before adding any supplement.

Where is MemoTril sold?

The supplement is available exclusively through the official website, per the company’s stated distribution policy. All transactions are processed through CartPanda Inc.

What refund policy does the company describe?

A 60-day money-back guarantee is described on the official website. Refund requests can be initiated through the company’s customer support team or through CartPanda’s support channel at support@cartpanda.com. Processing timelines depend on payment method and financial institution.

Is MemoTril safe?

The company states the supplement is made with natural ingredients and manufactured in an FDA-registered, GMP-certified facility. Consulting a healthcare provider before starting is recommended. Individual ingredients are generally well-studied for safety at typical supplemental dosages, though gastrointestinal side effects have been reported with Bacopa monnieri in some clinical studies, and Ginkgo biloba has known medication interactions.

Are the testimonials on the MemoTril website verified?

A disclosure at the bottom of the official website states that “some names and personal identifying information on this site have been changed to protect the privacy of individuals.” The standard FDA supplement disclaimer also appears. These disclosures are worth reviewing before relying on testimonial content to form expectations about personal outcomes.

Additional Consumer Research

As interest in cognitive support supplements continues to grow, experts generally recommend that consumers review ingredient transparency, examine available research, and consult qualified healthcare professionals before beginning any new supplement routine.

Consumers researching MemoTril may benefit from reviewing previously published independent reporting on this product. A 2026 product disclosure update examining MemoTril ingredient transparency and consumer interest in brain health supplement options provides additional context on what the company has publicly disclosed about its formula. Wellness researcher Holly Herman has also published an independent analysis of MemoTril consumer reviews and complaints examining real buyer feedback, refund experiences, and common concerns reported across multiple platforms.

Independent research across multiple consumer publications and peer-reviewed sources may provide broader perspective on nootropic supplements, brain health compounds, and cognitive support products. Evaluating multiple sources is recommended before making any purchasing decision. Consumers may also wish to review the FDA’s general guidance on dietary supplement labeling and claims.

Summary of Key Considerations

This report does not rate MemoTril as a product and does not recommend it. The purpose has been to examine publicly available information about MemoTril’s ingredient profile, marketing claims, pricing, and consumer-relevant disclosures.

MemoTril is a dietary supplement positioned as a natural cognitive support formula containing six ingredients with varying degrees of published ingredient-level research behind them. The company’s marketing materials describe the formula using language including “scientifically-proven ingredients” and state that the product has been used by thousands of customers. However, individual ingredient dosages are not publicly disclosed on the product page, and no published clinical trial has evaluated the finished product as formulated.

The company describes a 60-day refund guarantee, one-time purchase pricing, and states that the product is manufactured under GMP standards in an FDA-registered facility. Testimonials on the website are accompanied by a disclosure that names and personal details may have been changed.

Consumers researching cognitive supplements often weigh several factors, including ingredient transparency, manufacturing standards, refund policies, and whether published research exists for the compounds included in a formula. Those who have completed their own research and wish to review the full product details can do so. Complete product details, current pricing, and published terms are available by viewing the current MemoTril offer (official MemoTril page).

Contact Information

Company: MemoTril Research (Brand Owner)

Website: memotril.shop

Email: wellness@supportcaps.com

Payment Processor: CartPanda Inc., 555 Republic Dr, Plano, Texas 75074

Payment Processor Support: support@cartpanda.com

Disclaimers

Content and Consumer Information Disclaimer: This article is an independent informational overview and does not constitute medical, health, dietary, financial, or legal advice. All product details, ingredient information, pricing, and policy terms described in this article are stated as presented by the company on its publicly available website and product labeling. This content has not been independently audited or verified unless specifically noted. Readers are encouraged to verify all claims directly with the manufacturer and to consult a qualified healthcare professional before beginning any dietary supplement.

Supplement and Health Notice: Dietary supplements are not intended to diagnose, treat, cure, or prevent any disease. The statements made by the manufacturer regarding this product have not been evaluated by the Food and Drug Administration. Individual results vary based on numerous factors including age, baseline health, dietary habits, activity level, and consistency of use. Cognitive health concerns should be discussed with a qualified healthcare provider who is familiar with the individual’s personal medical history.

Results, Pricing, and Product Variability: All pricing, shipping terms, and refund policies referenced in this article are based on information published on the official product website at the time of writing and may change without notice. Consumers should verify current terms through the official website or the authorized payment processor before completing any purchase.

FTC Affiliate Disclosure and Publisher Responsibility: This article contains affiliate links. If a product is purchased through these links, a commission may be earned at no additional cost to the buyer. CartPanda Inc. serves as the authorized payment processor for this product. CartPanda’s role as payment processor does not constitute an endorsement, approval, or review of this product or any claim, statement, or opinion used in its promotion. The publisher of this article is not responsible for typographical errors, manufacturer changes to the product after publication, or individual consumer outcomes.

CONTACT: Email: wellness@supportcaps.com

Male Power XL “Black Elixir” Claims Evaluated: 2026 Report Examines Ingredient Research, Proprietary Blend Transparency, and What Men Should Verify Before Buying




Male Power XL “Black Elixir” Claims Evaluated: 2026 Report Examines Ingredient Research, Proprietary Blend Transparency, and What Men Should Verify Before Buying

A 2026 informational consumer report evaluating Male Power XL’s “black elixir” marketing language, ingredient research context, proprietary blend limitations, pricing and policy terms shown on the official site, and what men should verify before purchasing

New York, NY, March 03, 2026 (GLOBE NEWSWIRE) — This article contains affiliate links. If a purchase is made through these links, a commission may be earned at no additional cost to the buyer. This article is an informational overview and does not constitute medical, health, or dietary advice. All product details described below are stated as presented by the company and should be verified directly on the official website before any purchasing decision.

In this report, the term “enhancement” refers strictly to how Male Power XL’s marketing language describes potential outcomes. It does not indicate that the finished product has been clinically proven to produce performance-related outcomes, and no published clinical trial appears to evaluate Male Power XL as a proprietary formula.

If you’ve been searching for information about Male Power XL — especially the “black elixir” phrase used in its marketing — you’re not alone. The term appears in promotional materials and has become a common search phrase in the male vitality supplement category. This report treats “black elixir” as marketing terminology, not as proof of product-level clinical outcomes.

Male Power XL is a dietary supplement that positions itself as a natural male enhancement formula built around a blend of herbal extracts and botanical compounds. That level of visibility naturally brings questions. Are the ingredients in Male Power XL backed by published research? How do the product’s marketing claims compare to what the scientific literature actually supports at the ingredient level? And does the formula deliver meaningful amounts of its active compounds per serving?

This report does not recommend for or against Male Power XL. It summarizes what the company states, what published research suggests about certain listed ingredients under controlled study conditions, and what remains unknown due to proprietary blend dosing and the absence of product-level clinical trials.

This release is structured as an informational claims-evaluation report based on publicly available company materials and published research, not as a product endorsement.

Current product details, pricing, and terms can be confirmed by viewing the current Male Power XL offer (official Male Power XL page).

Individual results vary. Dietary supplements are not substitutes for balanced nutrition, regular physical activity, or professional medical guidance. Consult a qualified healthcare provider before starting any new supplement regimen, especially if you are currently taking prescription medications.

What Is Male Power XL

Male Power XL is a dietary supplement positioned as a natural male enhancement formula marketed for testosterone support, stamina, and sexual health. The company sells it in capsule form and describes it as a plant-based supplement option within the broader male vitality category. Per the product’s official website at boostmalepower.com, the supplement is distributed by Natural Wellness Solution d/b/a Male Power XL.

The company’s published product information states that Male Power XL is manufactured in the United States in an FDA-registered, GMP-certified facility. The website describes the formula as all-natural, non-GMO, and gluten-free. The product page lists a proprietary blend of herbal ingredients including Epimedium (Horny Goat Weed), Panax Ginseng, Tribulus Terrestris, Maca Root, L-Arginine, Tongkat Ali, Saw Palmetto, and Black Pepper Extract.

The supplement is marketed primarily toward men experiencing age-related changes in energy, libido, and physical performance. The company recommends consistent daily use over several months for what it describes as optimal results.

The “Black Elixir” Marketing: What Male Power XL Claims vs. What Research Can Confirm

The central marketing narrative behind Male Power XL connects the supplement to what the company describes as a “black elixir” — a phrase used on the product’s sales page and in promotional materials to characterize the formula. The sales page uses strong language to describe potential performance-related outcomes, positioning the supplement as a solution for men concerned about vitality and stamina.

These statements represent the seller’s marketing characterization of the product. They are not independently verified clinical outcomes, and the specific claims made in the company’s promotional materials go significantly beyond what published ingredient-level research has demonstrated for any individual compound in the formula.

The ingredients most closely associated with the product’s marketing claims have been studied individually in published peer-reviewed research — though the research context is important to understand before connecting those findings to this specific product.

L-Arginine, an amino acid listed in the formula, has been studied for its role as a precursor to nitric oxide, which supports blood vessel relaxation and circulation. A 2019 systematic review and meta-analysis published in the Journal of Sexual Medicine examined clinical trials on arginine supplements and found evidence supporting their use in mild to moderate erectile dysfunction. A separate 2022 randomized, double-blind, placebo-controlled trial studied L-arginine at a dose of 6 grams daily for three months and found statistically significant improvements in erectile function scores. Those are meaningful findings — but the dosages studied were substantially higher than what a multi-ingredient proprietary blend typically delivers per serving.

Tongkat Ali (Eurycoma longifolia), another key ingredient, has been the subject of a 2022 systematic review and meta-analysis published in Medicina that examined nine clinical trials. The review found a statistically significant increase in total testosterone levels in men receiving the extract, with the strongest results observed in men with low baseline testosterone. A separate six-month randomized, placebo-controlled trial found that 200 mg of Eurycoma longifolia combined with exercise improved erectile function scores in men experiencing age-related androgen decline.

These are real findings on real compounds. But there are important distinctions worth understanding before connecting that research to Male Power XL specifically.

The studies above tested individual ingredients at known, disclosed dosages under controlled conditions. Male Power XL uses a proprietary blend, meaning the total blend weight may be disclosed but the individual amounts of each ingredient are not listed on the label. Because FDA labeling rules require proprietary blend ingredients to appear by weight from highest to lowest, the position of each ingredient gives a general sense of proportion — but doesn’t reveal exact milligrams.

Consumers researching terms such as “Male Power XL results,” “does Male Power XL work,” “Male Power XL ingredients,” or “black elixir supplement” should understand that marketing claims referencing performance-related outcomes describe the seller’s characterization, not independently verified clinical results for this specific proprietary formula.

This evaluation doesn’t conclude whether Male Power XL has or lacks utility as a male health supplement. It focuses on clarifying how the performance-related marketing language should be interpreted when you’re doing your own research.

Male Power XL Ingredient Profile: What the Label Discloses

Based on publicly available product information, Male Power XL contains a proprietary blend of eight herbal ingredients: Epimedium (Horny Goat Weed), Panax Ginseng, Tribulus Terrestris, Maca Root, L-Arginine, Tongkat Ali, Saw Palmetto, and Black Pepper Extract. Several of these have individually been studied in published research for effects related to blood flow, testosterone modulation, libido, or sexual function — as detailed in the research section above.

A few additional notes on ingredients not covered above: Epimedium contains icariin, which has shown PDE5-inhibiting properties primarily in preclinical (non-human) research. Tribulus Terrestris is widely marketed for testosterone support, though clinical evidence on testosterone elevation in healthy men is mixed. Maca Root has published research suggesting possible benefits for libido at dosages typically ranging from 1,500 to 3,000 mg daily. Saw Palmetto is primarily studied for prostate health rather than sexual enhancement. Black Pepper Extract is commonly included as a bioavailability enhancer.

The key consideration is the proprietary blend structure. With eight ingredients sharing the total blend, it’s worth questioning whether multiple ingredients can simultaneously reach the individual dosages used in published clinical research. Without disclosed individual amounts, there’s no way to confirm or rule out research-level dosing from the label alone.

How Proprietary Blends Affect Research Comparison

Proprietary blends are common across the dietary supplement industry. They allow manufacturers to disclose which ingredients are included without revealing exact amounts for each one. This protects formulation trade secrets but limits your ability to evaluate whether individual ingredients are present at research-supported dosages.

Here’s why this matters practically. If L-Arginine research showing erectile function support used 6 grams daily, and Tongkat Ali research used 200 to 400 mg of standardized extract, and the entire Male Power XL blend contains a set total across eight ingredients — not all ingredients can be dosed at clinically studied levels simultaneously. Without individual milligram disclosures, you can’t verify this from the label. This isn’t unique to Male Power XL, but understanding how proprietary blends work helps set realistic expectations when marketing materials reference published research conducted at specific dosages.

Male Power XL Marketing Claims: Performance-Related Assertions in Context

The product’s sales page uses strong language to describe potential performance-related outcomes, featuring testimonials describing dramatic results alongside urgency-based pricing messaging. No published peer-reviewed clinical trial has demonstrated that any oral dietary supplement containing the ingredient profile listed for Male Power XL can produce the specific outcomes described in the company’s marketing materials. The individual ingredients have been studied for effects such as blood flow support, testosterone modulation, and libido enhancement — not the types of results referenced on the sales page.

The product’s own website includes the standard FDA disclaimer stating that its claims have not been evaluated by the Food and Drug Administration and that the product is not intended to diagnose, treat, cure, or prevent any disease. Men considering any supplement that makes performance-related claims should discuss those specific claims with a qualified healthcare provider before purchasing.

Male Power XL Testimonials: What Consumers Should Know

The official website includes customer testimonials describing specific performance-related outcomes attributed to named individuals with locations. The company’s Terms and Conditions page — published under the entity name Natural Wellness Solution d/b/a Male Power XL — contains standard legal disclaimers stating that the website’s content is provided “as is” and that the company is not rendering medical services or advice.

Across the supplement industry, it is common for product websites to feature testimonials representing exceptional rather than typical experiences. The specific outcomes described in testimonials on the Male Power XL website go significantly beyond what published ingredient-level research has demonstrated. Readers should factor this gap — and the company’s own disclaimer language — into how they interpret testimonial-based claims.

What Would Be Required to Prove Effectiveness

This is one of the most useful questions any consumer can ask about a supplement. For a dietary supplement to demonstrate effectiveness through clinical evidence, the standard generally includes a randomized, placebo-controlled trial using the finished product at its actual dosage, with results published in a peer-reviewed journal and subject to independent scrutiny.

As of this writing, no published clinical trial appears to have evaluated Male Power XL as a finished proprietary formula using this standard. The ingredients in the formula have published research at the individual compound level — some of it quite promising, particularly for L-Arginine and Tongkat Ali — but the gap between ingredient-level research and product-level proof remains open. Understanding this distinction isn’t about dismissing the product. It’s about knowing exactly what has and hasn’t been demonstrated so you can make a purchasing decision based on the actual evidence landscape.

Male Power XL Pricing and Purchase Structure

At the time of this report, the official website at boostmalepower.com listed multiple package options with different per-unit pricing and shipping terms. The site presents multi-bottle bundles as its primary purchase structure, with per-bottle pricing that decreases with larger orders. All purchases are described as one-time payments with no subscriptions or automatic rebilling.

Product pricing, shipping, bonuses, and policy details may change at any time, so readers should confirm current terms directly by viewing the current Male Power XL offer (official Male Power XL page).

Male Power XL Refund Policy and 180-Day Guarantee

The company publishes a 180-day return policy on its website. Consumers should read the full policy terms on the official site and retain order documentation in case a return request is needed. Refund processing timelines may vary by payment method and financial institution.

Consumer Verification Checklist: What to Confirm Before Ordering

Verify individual ingredient dosages. If exact amounts matter to you, contact the manufacturer directly — proprietary blends limit label-level comparison against published research dosages.

Separate ingredient research from product research. Many supplements reference published studies on individual compounds. Fewer have been tested as finished formulations through independent trials. Knowing the difference helps set realistic expectations.

Evaluate performance-related claims critically. Marketing claims describing specific outcomes should be weighed against published clinical evidence. If a claim sounds extraordinary, asking your healthcare provider for perspective is worthwhile.

Confirm refund terms and read disclaimers carefully. The fine print often contains important information about whether results are typical and what legal disclaimers apply. Confirm guarantee terms directly on the official website before purchasing.

Talk to your healthcare provider. This is especially important for men taking prescription medications for blood pressure, heart conditions, or diabetes. Some herbal ingredients can interact with pharmaceutical drugs, and a qualified clinician can assess potential risks specific to your situation.

Who Might Consider Male Power XL in 2026

Male Power XL is marketed toward adult men exploring supplement options in the male vitality category. The company’s positioning emphasizes plant-based ingredients and routine daily use as part of a broader wellness approach that can also include nutrition, exercise, sleep, and regular medical care.

As with any dietary supplement, suitability depends on individual health history, medications, and clinician guidance. Consumers who prefer fully disclosed per-ingredient dosing may want to verify label transparency details directly with the manufacturer before purchasing.

Consumer Questions About Male Power XL

What is the “black elixir” and how does it relate to Male Power XL?

The “black elixir” is a consumer-facing marketing term used on Male Power XL’s sales page to describe the supplement’s formula. It is not a recognized medical or pharmacological term. The phrase functions as a marketing descriptor designed to differentiate the product in a competitive supplement category.

Is Male Power XL FDA approved?

Male Power XL is a dietary supplement. Under current federal regulations, dietary supplements don’t require FDA approval before being sold. The FDA does not evaluate supplement efficacy claims. The website states the product is manufactured in an FDA-registered, GMP-certified facility, which relates to manufacturing standards rather than product approval or endorsement.

What ingredients are in Male Power XL?

Per publicly available product information, the formula includes Epimedium (Horny Goat Weed), Panax Ginseng, Tribulus Terrestris, Maca Root, L-Arginine, Tongkat Ali, Saw Palmetto, and Black Pepper Extract. The supplement uses a proprietary blend, meaning exact individual ingredient amounts are not disclosed on the label.

Can Male Power XL produce specific performance-related outcomes?

The seller’s marketing materials describe specific performance-related claims. No published clinical trial appears to evaluate Male Power XL’s proprietary formula for those specific outcomes. Individual ingredient research on compounds like L-Arginine examines blood flow support and erectile function — not the kind of outcomes described in the company’s marketing. Men with specific health questions should consult a qualified healthcare provider.

Are the testimonials on the Male Power XL website verified?

The website features testimonials describing exceptional outcomes. The company’s general disclaimer states that content is provided “as is” and that the company is not rendering medical advice. Testimonial outcomes should be interpreted alongside the disclaimers published on the website, and consumers should understand that exceptional results do not reflect typical experiences.

What is the Male Power XL refund policy?

The published policy provides a 180-day window for return requests. Consumers should read the full policy terms on the official site and retain order documentation. Processing timelines depend on your payment method and financial institution.

What does “FDA-registered facility” mean?

An FDA-registered facility is a manufacturing location that has registered with the FDA as required by federal law. Registration means the facility is subject to FDA inspection. It doesn’t mean the FDA has reviewed, approved, or endorsed any specific product manufactured at that location.

Is Male Power XL safe to take with medications?

Several ingredients in the formula, including Panax Ginseng, Tongkat Ali, and L-Arginine, have been noted in published literature for potential interactions with certain medications, particularly blood pressure medications, blood thinners, and diabetes treatments. Consulting a healthcare provider before combining any herbal supplement with prescription medications is strongly recommended.

How long does Male Power XL take to show results?

The company’s materials describe a range of timelines for noticing changes, but individual experiences can vary widely based on age, baseline health, lifestyle, and consistency of use. Consumers should interpret timeline language as marketing context rather than product-level clinical proof and discuss expectations with a qualified healthcare provider.

Where is Male Power XL sold?

According to the company, Male Power XL is sold exclusively through its official website at boostmalepower.com. The site recommends purchasing directly to ensure product authenticity and eligibility for the published return policy.

Additional Consumer Research

Independent research across multiple consumer publications and peer-reviewed sources may provide broader perspective on male enhancement supplements, botanical ingredients commonly used in men’s health formulas, and dietary supplement evaluation standards. Evaluating multiple sources is recommended before making any purchasing decision. Consumers may also wish to review the FDA’s general guidance on dietary supplement labeling and claims, as well as the FTC’s guidelines on advertising for dietary supplements.

Summary of Key Considerations

Male Power XL is a dietary supplement built around the “black elixir” marketing concept and a proprietary blend of herbal ingredients common in the male enhancement category. The formula contains compounds with published ingredient-level research — particularly L-Arginine for blood flow support and Tongkat Ali for testosterone modulation — though the proprietary blend limits visibility into individual dosing, and no published clinical trial has evaluated the finished product as formulated.

The company’s marketing describes specific performance-related outcomes that go beyond what published ingredient-level research has demonstrated. The product carries a 180-day return policy, one-time purchase pricing, and is stated to be manufactured under GMP standards in an FDA-registered facility.

Consumers who have completed their own research and want to see full product details can do so. Complete product details, current pricing, and published terms are available by viewing the current Male Power XL offer (official Male Power XL page).

Contact Information

Company: Natural Wellness Solution d/b/a Male Power XL

Website: https://boostmalepower.com/

Email: info@malepowersupport.com

Phone Support: 302-200-3480

Disclaimers

Content and Consumer Information Disclaimer: This article is an independent informational overview and does not constitute medical, health, dietary, financial, or legal advice. All product details, ingredient information, pricing, and policy terms described in this article are stated as presented by the company on its publicly available website and product labeling. This content has not been independently audited or verified unless specifically noted. Readers are encouraged to verify all claims directly with the manufacturer and to consult a qualified healthcare professional before beginning any dietary supplement.

Supplement and Health Notice: Dietary supplements are not intended to diagnose, treat, cure, or prevent any disease. The statements made by the manufacturer regarding this product have not been evaluated by the Food and Drug Administration. Individual results vary based on numerous factors including age, baseline health, dietary habits, activity level, and consistency of use. Male health concerns should be discussed with a qualified healthcare provider who is familiar with the individual’s personal medical history.

Results, Pricing, and Product Variability: All pricing, bonus offers, shipping terms, and refund policies referenced in this article are based on information published on the official product website at the time of writing and may change without notice. Consumers should verify current terms through the official website before completing any purchase.

FTC Affiliate Disclosure and Publisher Responsibility: This article contains affiliate links. If a product is purchased through these links, a commission may be earned at no additional cost to the buyer. The publisher of this article is not responsible for typographical errors, manufacturer changes to the product after publication, or individual consumer outcomes.

CONTACT: Email: info@malepowersupport.com
Phone Support: 302-200-3480

AudiLeaf Ear Health Claims Evaluated: 2026 Report Examines Ingredients, Proprietary Blend Dosing, and What Consumers Should Verify Before Buying




AudiLeaf Ear Health Claims Evaluated: 2026 Report Examines Ingredients, Proprietary Blend Dosing, and What Consumers Should Verify Before Buying

A 2026 informational consumer evaluation of AudiLeaf’s ear health marketing claims, proprietary herbal blend ingredient research context, pricing structure, and what to verify before purchasing

Aurora, CO, March 03, 2026 (GLOBE NEWSWIRE) — This article contains affiliate links. If a purchase is made through these links, a commission may be earned at no additional cost to the buyer. This article is an informational overview and does not constitute medical, health, or dietary advice. All product details described below are stated as presented by the company and should be verified directly on the official website before any purchasing decision.

Disclaimer: This article is for informational purposes only. It is not medical advice. Always consult a qualified healthcare professional before starting supplements. If you purchase through links in this article, a commission may be earned at no additional cost to you.

In this report, terms like “support” or “effectiveness” refer only to how the company describes intended use and do not indicate product-level clinical proof. No published clinical trial evaluating AudiLeaf as a finished proprietary formula was identified in publicly available sources reviewed for this report.

If you’ve been researching natural hearing support supplements online, you’ve probably come across AudiLeaf. Interest in plant-based ear health formulas has been growing — especially among adults who are noticing age-related changes in hearing comfort or mental focus and want to explore what’s available before making a decision.

Sold as a liquid dietary supplement built around a proprietary herbal blend, AudiLeaf is marketed for ear health, brain function, and nervous system support. With that positioning come practical questions. Does the formula contain ingredients with published research behind them? How does the proprietary blend structure affect what consumers can verify about dosing? And what should buyers confirm before placing an order?

This report does not recommend for or against AudiLeaf. It summarizes what the company states, what ingredient-level research suggests generally, and what consumers should verify independently before purchasing.

Current product details, pricing, and terms can be confirmed by viewing the current AudiLeaf offer (official AudiLeaf page).

Individual results vary. Dietary supplements are not substitutes for balanced nutrition, regular physical activity, or professional medical guidance. Consult a qualified healthcare provider before starting any new supplement regimen.

What Is AudiLeaf

AudiLeaf is a liquid dietary supplement marketed as a formula for ear health, cognitive function, and nervous system support. The company sells it as a once-daily dropper-based supplement and positions it as a plant-based option for adults concerned about hearing clarity and mental focus.

The company’s materials state that AudiLeaf is distributed from Aurora, Colorado. Consumers who want manufacturing-location details may wish to confirm them directly with AudiLeaf. The label lists the supplement in liquid form, with a serving size of 1 mL (approximately two droppers full) and 30 servings per container.

Each serving contains a proprietary herbal blend totaling 200 mg, along with 7 mcg of Chromium as Chromium Picolinate (20% Daily Value). Other ingredients include water, flavoring, potassium sorbate, xylitol, stevia, and citrus extract.

The label includes the standard FDA disclaimer stating that the product’s claims have not been evaluated by the Food and Drug Administration and that the product is not intended to diagnose, treat, cure, or prevent any disease.

AudiLeaf Ear Health Claims: What the Company States vs. What Research Can Confirm

The central marketing narrative behind AudiLeaf positions the product as “one of the most advanced formulas for ear, brain, and nervous system health.” The sales page describes the supplement as “carefully formulated to support healthy hearing, sharpen mental clarity, and support peace of mind.”

The website lists several benefit claims, including supporting clear hearing and ear health, enhancing cognitive function and mental focus, promoting everyday ear comfort, and supporting nervous system health. These claims are accompanied by the standard FDA disclaimer required for dietary supplements.

The product’s proprietary herbal blend contains twenty-one ingredients sharing a total of 200 mg. Several of these ingredients have been individually studied in published research for properties that may relate to auditory or cognitive health — though the research was conducted on isolated compounds at known dosages, not on AudiLeaf’s specific formula.

Grape Seed Extract has been studied for its antioxidant properties, particularly its proanthocyanidin content. Published research suggests these compounds may help protect cells from oxidative stress. Some reviews in peer-reviewed nutrition literature have examined grape seed proanthocyanidins and their role in reducing oxidative damage across multiple biological systems. Oxidative stress has been identified in published literature as one contributing factor in age-related changes to auditory function.

Green Tea Leaf Extract contains catechins, including EGCG, which have been studied for antioxidant and anti-inflammatory properties. Peer-reviewed nutrition literature has examined green tea catechins in the context of antioxidant and inflammatory pathways, with some research suggesting these compounds may support vascular health and help reduce inflammatory markers.

Astragalus Root Extract has a long history in traditional Chinese medicine and has been studied for immune-modulating and antioxidant properties. Scientific literature has examined astragalus compounds for their potential effects on cellular health and inflammation response.

GABA (Gamma-Aminobutyric Acid) is a naturally occurring neurotransmitter that has been studied for its calming effects on the nervous system. Published research has explored oral GABA supplementation for stress reduction and relaxation, though the bioavailability of oral GABA remains a topic of ongoing scientific discussion.

These studies examined isolated compounds at disclosed dosages under specific research conditions. They did not evaluate AudiLeaf as a finished multi-ingredient liquid supplement.

Consumers researching terms such as “AudiLeaf hearing support,” “does AudiLeaf work,” “AudiLeaf ear health results,” or “AudiLeaf tinnitus” should understand that marketing claims referencing ingredient-level properties describe general research findings on individual compounds, not product-level clinical outcomes verified through independent testing of the finished supplement.

This evaluation doesn’t conclude whether AudiLeaf has or lacks utility as an ear health support formula. It focuses on clarifying how the marketing language should be interpreted when you’re doing your own research.

AudiLeaf Ingredient Profile: What the Label Discloses

The AudiLeaf Supplement Facts panel lists the following per one-milliliter serving:

Chromium (as Chromium Picolinate): 7 mcg — 20% Daily Value

Proprietary Herbal Blend: 200 mg, containing Maca Root Extract, African Mango Seed Extract, Grape Seed Extract, Guarana Seed Extract, Eleutherococcus Senticosus Root Extract, Astragalus Membranaceus Root Extract, Green Tea Leaf Extract, Gymnema Sylvestre Leaf Extract, Coleus Forskohlii Root Extract, Cayenne Pepper Fruit Extract, Grapefruit Seed Extract, Ginseng Root Extract, Raspberry Ketones, L-Glutamine, L-Tyrosine, L-Arginine, Beta Alanine, Monoammonium Glycyrrhizinate, GABA (Gamma Aminobutyric Acid), L-Tryptophan, and L-Carnitine HCl.

Other Ingredients: Water, Flavoring, Potassium Sorbate, Xylitol, Stevia, Citrus Extract (Glycerin, Lactic Acid, Citric Acid).

The label notes that certain botanical extracts are sourced from concentrates with a 20:1 extract equivalent, and others with a 10:1 extract equivalent. These ratios suggest concentrated forms of certain ingredients, though specific milligram equivalencies per serving are not disclosed on the label.

The key consideration for anyone evaluating this formula is the proprietary blend structure. Because the blend totals 200 mg across twenty-one ingredients, individual ingredient amounts may be lower than the dosages commonly used in standalone studies, which can limit direct comparison to published research. For context, published research on grape seed extract for antioxidant effects commonly uses 100 to 300 mg daily. Green tea extract studies examining cellular protection typically use 400 to 600 mg of catechins. Oral GABA supplementation studies have generally used 100 to 200 mg per dose.

That doesn’t mean the product has no effect. It means that if you’re comparing AudiLeaf’s formula to published research, the dosing context is worth factoring into your own evaluation.

How Proprietary Blends Affect Research Comparison

Proprietary blends are common across the dietary supplement industry. They allow manufacturers to disclose which ingredients are included without revealing exact amounts for each one. This protects formulation trade secrets but limits a consumer’s ability to evaluate whether individual ingredients are present at research-supported dosages.

A full-disclosure label, by contrast, lists each ingredient with its specific dosage per serving. That format lets consumers and healthcare providers compare dosages directly against amounts used in published studies and against competing products. Many supplements in the ear health category use proprietary blends, so understanding how they work helps set realistic expectations when marketing materials reference ingredient-level research conducted at specific, known dosages.

Ear Health Supplements in 2026: Category Context

The ear health supplement category has expanded considerably over the past two years. Products in this space typically position themselves around antioxidant protection for auditory cells, improved blood circulation to the inner ear, nervous system calming and neural support, and anti-inflammatory effects on auditory pathways. Delivery formats range from capsules to liquid droppers.

Consumers evaluating products in this category benefit from comparing several factors: individual ingredient disclosure versus proprietary blend structures, total active ingredient amounts per serving, the presence or absence of product-level clinical trials, refund policy terms, and published contact information for the company.

No dietary supplement in this category has received FDA approval for the treatment of hearing loss, tinnitus, or any diagnosed auditory condition. Supplements are regulated differently than pharmaceutical drugs, and the FDA does not evaluate dietary supplement claims for efficacy before products reach the market.

AudiLeaf Pricing and Purchase Structure

According to pricing information published on the official website at the time of this report, AudiLeaf is presented in multi-bottle packages. A single bottle (30-day supply) is listed at $79 per bottle with $9.99 shipping. A three-bottle package (described as a 90-day supply) is listed at $69 per bottle with free U.S. shipping, totaling $177. A six-bottle package is listed at $49 per bottle with free U.S. shipping, totaling $294.

All purchases are described as one-time payments. The bonus digital guides included with multi-bottle packages — described as “The Quiet Mind Blueprint” and “Ear & Brain Secrets” — are supplementary wellness and personal development resources provided at no additional charge with qualifying orders.

Pricing and availability can change, so readers should verify current terms by viewing the current AudiLeaf offer (official AudiLeaf page).

AudiLeaf Refund Policy and Money-Back Guarantee

The AudiLeaf website contains references to different refund-window descriptions in different sections. Some pages reference a 60-day money-back guarantee, while other sections describe a 180-day guarantee period. Because published terms can change or be presented differently across pages, consumers should confirm the currently applicable return window and return requirements directly on the official AudiLeaf website before ordering.

The refund policy section indicates that all bottles — whether empty, full, or partially full, including any bonus or free bottles — must be returned to the company’s Aurora, Colorado fulfillment address within the applicable guarantee period. The consumer is responsible for return shipping costs. The policy states that failure to return all bottles may result in a partial refund.

After processing a refund request, the company sends confirmation via email. The published refund page notes that credit card refunds may take several business days and debit card refunds may take somewhat longer, depending on the issuing institution’s processing schedule.

It is worth reviewing the complete refund policy on the official website, confirming which guarantee window currently applies, and holding on to all purchase confirmation details before ordering.

AudiLeaf Testimonials: What Consumers Should Know

The official website includes customer testimonials describing subjective experiences such as changes in perceived hearing comfort, sleep quality, and daily energy. These testimonials are attributed to named individuals with state locations and note that the individuals purchased specific bottle quantities.

Readers should approach testimonial content with appropriate context. Dietary supplement testimonials reflect individual experiences that may not be representative of typical outcomes. Results depend on numerous personal health factors, and the supplement’s labeling includes the standard FDA disclaimer.

The company’s terms of service include standard disclaimers noting that the site offers health and wellness information for educational purposes only. Per those terms, the information should not be relied upon as a substitute for professional medical advice, diagnosis, or treatment.

What Would Be Required to Prove Effectiveness

For a dietary supplement to demonstrate effectiveness through clinical evidence, the standard generally includes a randomized, placebo-controlled trial using the finished product at its actual dosage, with disclosed formulation, defined endpoints, and a representative study population. Results would typically be published in a peer-reviewed journal.

As of this writing, no published clinical trial appears to have evaluated AudiLeaf as a finished proprietary formula using this standard. The ingredient-level research that may be relevant to individual compounds in the blend was conducted on isolated ingredients at specific dosages — not on the liquid formulation as sold. That is common across the supplement industry, but it means the gap between ingredient-level research and product-level proof remains open.

Understanding this distinction isn’t about dismissing the product. It’s about knowing exactly what has and hasn’t been demonstrated — so you can make a purchasing decision based on the actual evidence landscape, not how marketing materials frame it.

Consumer Verification Checklist: What to Confirm Before Ordering

Verify individual ingredient dosages. Proprietary blends limit dosage comparison — if exact amounts matter to you, contact the manufacturer directly.

Separate ingredient research from product research. Many supplements reference published studies on individual compounds. Fewer have been tested as finished formulations. Knowing the difference helps set realistic expectations.

Confirm refund terms independently. Review guarantee terms, return requirements, and processing timelines on the official website before purchasing. Note that the AudiLeaf refund policy requires all bottles to be returned and that the consumer pays return shipping.

Talk to your healthcare provider. This is especially important for adults experiencing hearing changes, taking prescription medications, or managing chronic conditions. Hearing concerns should be evaluated by a qualified audiologist or physician to rule out underlying medical conditions.

Who Might Consider AudiLeaf in 2026

Based on the product’s published positioning and ingredient profile, AudiLeaf may be of interest to adults who prefer plant-based liquid supplement options and who are exploring nutritional approaches to auditory wellness as one component of a broader health strategy that includes regular medical checkups and hearing evaluations.

The product may be less suited for consumers who require transparent individual ingredient dosing for clinical comparison, those seeking evidence-based interventions for diagnosed hearing conditions, or anyone expecting rapid changes from a single supplement without accompanying professional medical guidance.

As with any dietary supplement, individual outcomes depend on a wide range of personal health factors. Supplements are regulated differently than pharmaceutical drugs, and the FDA does not evaluate dietary supplement claims for efficacy before products reach the market. The FDA disclaimer printed on AudiLeaf’s own label confirms that the product’s statements have not been evaluated by the Food and Drug Administration and that the product is not intended to diagnose, treat, cure, or prevent any disease.

Consumer Questions About AudiLeaf

What is AudiLeaf, and what does it claim to do?

Marketed as a liquid dietary supplement for ear health, cognitive function, and nervous system support, AudiLeaf is positioned as a plant-based formula designed to support hearing clarity, mental focus, and a sense of calm. These are marketing descriptions, not clinically validated medical claims.

Is AudiLeaf FDA approved?

As a dietary supplement, AudiLeaf does not require FDA approval before being sold under current federal regulations. The FDA does not evaluate supplement efficacy claims. The product label includes the standard FDA disclaimer confirming this.

What ingredients are in AudiLeaf?

The supplement contains a proprietary herbal blend of twenty-one ingredients totaling 200 mg, along with 7 mcg of Chromium as Chromium Picolinate. Ingredients include Maca Root Extract, African Mango Seed Extract, Grape Seed Extract, Green Tea Leaf Extract, GABA, L-Glutamine, L-Tyrosine, L-Arginine, and several other botanical and amino acid compounds. Because it uses a proprietary blend, individual ingredient amounts are not disclosed.

How do I take AudiLeaf?

Per the label’s directions, the recommended serving is 1 mL (approximately two droppers full) taken once daily, or as directed by a healthcare professional.

Does AudiLeaf contain caffeine or stimulants?

The formula includes Guarana Seed Extract and Green Tea Leaf Extract, both of which naturally contain caffeine. The specific caffeine content per serving is not disclosed on the label. Consumers sensitive to caffeine should consult their healthcare provider before use.

Can I verify the research behind AudiLeaf’s ingredients?

Individual ingredients in the blend — such as grape seed extract, green tea extract, and GABA — have been studied in published peer-reviewed research. You can look up these studies in PubMed or relevant journal databases. Keep in mind that published research examines individual compounds at specific dosages, not AudiLeaf’s proprietary liquid formula as a finished product.

Why does AudiLeaf use a proprietary blend?

Proprietary blends allow manufacturers to disclose which ingredients are included without revealing exact amounts for each one. This protects formulation trade secrets but limits your ability to compare individual ingredient dosages against published research ranges. With twenty-one ingredients sharing 200 mg, the dosing math is worth considering.

How long does AudiLeaf take to show results?

The company’s FAQ suggests that many users report improvements after consistent use, though specific timelines are not guaranteed. Individual response timelines depend on factors including baseline health, dietary habits, and consistency of use.

What is AudiLeaf’s refund policy?

The website references different guarantee windows in different sections. The refund policy section describes a return process requiring all bottles to be sent back within the applicable guarantee period. The consumer pays return shipping. Because terms may be presented differently across pages, it’s worth confirming the current refund window directly on the official site before ordering.

Is AudiLeaf safe to take with medications?

The label’s caution section recommends consulting with a physician prior to use, especially if you are taking a medication or have a medical condition. This is particularly important given that the formula contains multiple botanical extracts and amino acids that may interact with certain medications.

Where is AudiLeaf sold?

Based on the company’s published information, AudiLeaf appears to be available through the official website. The site advises consumers to purchase through official channels to ensure product authenticity and refund eligibility.

Is AudiLeaf suitable for all adults?

The supplement label states it is not for use by those under 18 or by pregnant or nursing mothers. The label also recommends not exceeding the recommended dose and keeping the product out of reach of children. Adults with existing medical conditions should consult a healthcare provider before use.

Additional Consumer Research

Independent research across multiple consumer publications and peer-reviewed sources may provide broader perspective on ear health supplements, auditory wellness products, and the ingredients commonly used in this category. Evaluating multiple sources is recommended before making any purchasing decision. Consumers may also wish to review the FDA’s general guidance on dietary supplement labeling and claims.

Summary of Key Considerations

As a liquid dietary supplement, AudiLeaf positions itself as a formula for ear health, cognitive function, and nervous system support. The product contains ingredients that have been individually studied in published research for antioxidant, anti-inflammatory, and circulatory properties. However, the proprietary blend structure — with twenty-one ingredients sharing a 200 mg total — limits visibility into individual dosing, and no published clinical trial has evaluated the finished product as formulated.

The company describes a money-back guarantee, one-time purchase pricing, and published contact information for customer support. Testimonials on the website are accompanied by standard disclaimers. The supplement’s packaging includes the required FDA statement that the supplement has not been evaluated for the diagnosis, treatment, cure, or prevention of any disease.

This report does not recommend for or against AudiLeaf.

If you’ve done your own research and want to see the full product details firsthand, complete product information, current pricing, and published terms are available by viewing the current AudiLeaf offer (official AudiLeaf page).

Contact Information

Company: AudiLeaf

Return Address: 19655 E 35th Dr., Suite 100, Aurora, CO 80011, USA

Email: support@audileaf.com

Phone: The AudiLeaf website and label materials list multiple customer service numbers, including +1 (720) 248-8973 and +1 (720) 513-2923. Consumers should confirm the current support number on the official website at the time of purchase.

Disclaimers

Content and Consumer Information Disclaimer: This article is an independent informational overview and does not constitute medical, health, dietary, financial, or legal advice. All product details, ingredient information, pricing, and policy terms described in this article are stated as presented by the company on its publicly available website and product labeling. This content has not been independently audited or verified unless specifically noted. Readers are encouraged to verify all claims directly with the manufacturer and to consult a qualified healthcare professional before beginning any dietary supplement.

Supplement and Health Notice: Dietary supplements are not intended to diagnose, treat, cure, or prevent any disease. The statements made by the manufacturer regarding this product have not been evaluated by the Food and Drug Administration. Individual results vary based on numerous factors including age, baseline health, dietary habits, activity level, and consistency of use. Hearing health concerns should be discussed with a qualified healthcare provider or audiologist who is familiar with the individual’s personal medical history.

Results, Pricing, and Product Variability: All pricing, bonus offers, shipping terms, and refund policies referenced in this article are based on information published on the official product website at the time of writing and may change without notice. Consumers should verify current terms through the official website before completing any purchase.

FTC Affiliate Disclosure and Publisher Responsibility: This article contains affiliate links. If a product is purchased through these links, a commission may be earned at no additional cost to the buyer. The publisher of this article is not responsible for typographical errors, manufacturer changes to the product after publication, or individual consumer outcomes.

CONTACT: Email: support@audileaf.com

ATI Advisory Welcomes Former Wisconsin Medicaid Director Bill Hanna as Practice Director of Payer Strategy and Program Design




ATI Advisory Welcomes Former Wisconsin Medicaid Director Bill Hanna as Practice Director of Payer Strategy and Program Design

Washington, DC, March 03, 2026 (GLOBE NEWSWIRE) — ATI Advisory (ATI), a leading healthcare consulting firm, today announced that Bill Hanna has joined the firm as Practice Director of Payer Strategy and Program Design. Hanna is a public sector executive and former Wisconsin Medicaid Director with extensive experience leading complex health and human services systems at the state and local level. He brings a deep understanding of Medicaid policy, managed care delivery, and large-scale operational transformation, further strengthening ATI’s rapidly expanding payer strategy platform at a pivotal moment for state Medicaid programs and managed care organizations.

As Wisconsin Medicaid Director, Hanna oversaw a multibillion-dollar program serving hundreds of thousands of beneficiaries across the state. He led initiatives to strengthen managed care performance, maintain member eligibility, advance value-based purchasing strategies, and improve integration across physical health, behavioral health, and long-term services and supports. His leadership required close coordination with federal partners, managed care organizations, providers, advocates, and legislators in a highly visible and dynamic environment to strengthen access, accountability, and fiscal sustainability.

Hanna has also held leadership roles at UnitedHealthcare and the District of Columbia Department of Health Care Finance. Across these positions, he led high-stakes initiatives involving procurement strategy, delivery system reform, market expansion, and operational transformation in competitive and highly regulated environments.

At ATI, Hanna will lead the firm’s payer strategy and program design work, advising public and private clients navigating tightening fiscal conditions, evolving federal requirements, value-based payment expansion, and increased regulatory scrutiny. He will advise clients on growth, market positioning, and program transformation, leaning into deep cross-sector experience in policy, strategy, financing, and operational execution. “As healthcare leaders confront heightened competition, fiscal pressure, rapid technological change, and regulatory complexity, ATI is investing in the leadership and capabilities required to meet this moment,” said Anne Tumlinson, Founder and CEO of ATI Advisory. “Bill brings rare credibility across state government and managed care. His leadership will accelerate our ability to help clients compete, grow, strengthen operations and make healthcare better for everyone.”

“States and health plans are operating in one of the most dynamic and uncertain periods in Medicaid’s history — a time that presents both disruption and real opportunity,” said Hanna. “Success requires more than policy knowledge; it demands stakeholder trust and clear alignment between mission and market strategy. Organizations that can translate complexity into operational clarity will be best positioned to lead. ATI sits at the intersection of policy insight and execution, and I’m excited to help clients strengthen programs, compete effectively, and drive sustainable growth while improving care for the people who rely on these systems every day.”

Hanna’s appointment reflects ATI’s continued expansion in payer strategy and its commitment to serving as a national leader in Medicaid and Medicare market advisory services. As managed care markets grow more competitive and performance-driven, ATI is scaling its capabilities to support clients seeking strategic advantage, operational excellence, and long-term sustainability.

About ATI Advisory

ATI Advisory is a healthcare research and advisory services firm dedicated to system reform that improves health outcomes and makes care better for everyone. ATI guides public and private leaders in solving the most complex problems in healthcare through objective research, deep expertise, and bringing ideas to action.

Press Inquiries

Olivia Blumenshine
communications@atiadvisory.com
https://atiadvisory.com/

Quipt Home Medical Announces Voting Results From Special Meeting of Shareholders




Quipt Home Medical Announces Voting Results From Special Meeting of Shareholders

CINCINNATI, March 03, 2026 (GLOBE NEWSWIRE) — Quipt Home Medical Corp. (the “Company”) (NASDAQ: QIPT; TSX: QIPT)‎, a U.S. based home medical equipment provider, focused on end-to-end respiratory care, today announced the voting results from its special meeting of holders (the “Shareholders”) of common shares (the “Shares”) of the Company held on March 3, 2026 (the “Meeting”) in Sarasota, Florida. The Shareholders voted to approve the special resolution (the “Arrangement Resolution”) approving the plan of arrangement under the Business Corporations Act (British Columbia), involving, among other things, the acquisition by affiliates of Kingswood Capital Management, L.P. and Forager Capital Management, LLC of all of the issued and outstanding Shares (the “Arrangement”) for cash consideration of US$3.65 per Share.

The Arrangement Resolution required approval of: (i) at least 66⅔% of the votes cast by Shareholders, present in person or represented by proxy at the Meeting; and (ii) in accordance with Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101”), a simple majority of votes cast by the Shareholders, present in person or represented by proxy and entitled to vote at the Meeting, excluding the votes in respect of Shares cast by any “interested party”, any “related party” of an “interested party” or any “joint actor” (as such terms are defined in MI 61-101). Shareholders holding 29,672,136 Shares, representing approximately 66.93% of the outstanding Shares, were represented in person or by proxy at the Meeting. The Arrangement Resolution was approved by: (i) Shareholders holding 98.9% of the Shares voted; and (ii) Shareholders holding 98.7% of the Shares voted, after excluding the votes cast by the Shareholders whose votes were required to be excluded in determining minority approval under MI 61-101.

The Company is scheduled to seek a final order of the Supreme Court of British Columbia approving the Arrangement on March 5, 2026. Assuming all other terms and conditions, including applicable stock exchange and regulatory approvals, to the Arrangement are satisfied, it is expected that the Arrangement will be completed in the near term. Further information about the Arrangement can be found in the Company’s definitive proxy statement and management information circular dated January 23, 2026 for the Meeting, which is available under the Company’s profile on SEDAR+ and on the Company’s website https://quipthomemedical.com., and has been filed with the SEC on the EDGAR website at www.sec.gov.

A Form 8-K in respect of the voting results has been filed with the SEC on the EDGAR website at www.sec.gov, on SEDAR+ under the Company’s issuer profile at www.sedarplus.com.

ABOUT QUIPT HOME MEDICAL CORP.‎

The Company provides in-home monitoring and disease management services including end-to-end respiratory solutions for patients in the United States healthcare market. It seeks to continue to expand its offerings to include the management of several chronic disease states focusing on patients with heart or pulmonary disease, sleep disorders, reduced mobility, and other chronic health conditions. The primary business objective of the Company is to create shareholder value by offering a broader range of services to patients in need of in-home monitoring and chronic disease management. The Company’s organic growth strategy is to increase annual revenue per patient by offering multiple services to the same patient, consolidating the patient’s services, and making life easier for the patient.‎

FORWARD-LOOKING STATEMENTS

Certain statements contained in this press release constitute “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 or “forward-looking information” as such term is defined in applicable Canadian securities legislation (collectively, “forward-looking statements”). The words “may”, “would”, “could”, “should”, “potential”, “will”, “seek”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “postulate”, “expect”, “outlook”, or the negatives thereof or variations of such words, and similar expressions as they relate to the Company are intended to identify forward-looking statements, including: the proposed Arrangement and terms thereof; and the anticipated completion of the Arrangement, including receipt of court and regulatory approval and satisfaction of closing conditions; and other statements that are not historical fact. All statements other than statements of historical fact, including those that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-looking statements and may involve estimates, assumptions and uncertainties that could cause actual results or outcomes to differ materially from those expressed in the forward-looking statements. Such statements reflect the Company’s current views and intentions with respect to future events, and current information available to the Company, and are subject to certain risks, uncertainties and assumptions, including, without limitation: the ability to obtain the necessary regulatory, court, and other third party approvals for the Arrangement, the timing of obtaining such approvals and the risk that such approvals may not be obtained in a timely manner or at all, and the risk that such approvals may be obtained on conditions that are not anticipated; the timing of closing of the Arrangement; the risk that the conditions to the Arrangement are not satisfied on a timely basis or at all and the failure of the Arrangement to close for any other reason; the delisting of the Shares from the TSX and NASDAQ; the Company ceasing to be a reporting issuer under Canadian and U.S. federal securities laws and the timing thereof; the abilities of the parties to satisfy, in a timely manner, the other conditions to the closing of the Arrangement; the failure of the Arrangement to close for any other reason; and the ability to achieve the expected benefits of the Arrangement. Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward-looking statements to vary from those described herein should one or more of these risks or uncertainties materialize. Examples of such risk factors include, without limitation: risks related to credit, market (including equity, commodity, foreign exchange and interest rate), liquidity, operational (including technology and infrastructure), reputational, insurance, strategic, regulatory, legal, environmental, and capital adequacy; the general business and economic conditions in the regions in which the Company operates; the ability of the Company to execute on key priorities, including the successful completion of acquisitions, business retention, and strategic plans and to attract, develop and retain key executives; difficulty integrating newly acquired businesses; the ability to implement business strategies and pursue business opportunities; low profit market segments; disruptions in or attacks (including cyber-attacks) on the Company’s information technology, internet, network access or other voice or data communications systems or services; the evolution of various types of fraud or other criminal behavior to which the Company is exposed; the failure of third parties to comply with their obligations to the Company or its affiliates; the impact of new and changes to, or application of, current laws and regulations; decline of reimbursement rates; dependence on few payors; possible new drug discoveries; a novel business model; dependence on key suppliers; granting of permits and licenses in a highly regulated business; legal proceedings and litigation, including as it relates to the civil investigative demand received from the Department of Justice; increased competition; changes in foreign currency rates; the imposition of trade restrictions such as tariffs and retaliatory counter measures; increased funding costs and market volatility due to market illiquidity and competition for funding; the availability of funds and resources to pursue operations; critical accounting estimates and changes to accounting standards, policies, and methods used by the Company; the Company’s status as an emerging growth company and a smaller reporting company; the occurrence of natural and unnatural catastrophic events or health epidemics or concerns; as well as those risk factors discussed or referred to in the Company’s disclosure documents filed with the SEC and available on EDGAR at www.sec.gov, including the Company’s most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, and with the securities regulatory authorities in certain provinces of Canada and available at www.sedarplus.ca. Should any factor affect the Company in an unexpected manner, or should assumptions underlying the forward-looking statement prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking statements are expressly qualified in their entirety by this cautionary statement. Moreover, the Company does not assume responsibility for the accuracy or completeness of such forward-looking statements. The forward-looking statements included in this press release are made as of the date of this press release and the Company undertakes no obligation to publicly update or revise any forward-looking statements, other than as required by applicable law.

For further information please visit our website at www.quipthomemedical.com, or contact:‎
Cole Stevens
VP of Corporate Development
Quipt Home Medical Corp.
‎859-300-6455
cole.stevens@myquipt.com

Gregory Crawford
Chief Executive Officer
Quipt Home Medical Corp.
‎859-300-6455
investorinfo@myquipt.com

Teva and Blackstone Life Sciences Announce $400 Million Strategic Growth Capital Agreement to Advance duvakitug




Teva and Blackstone Life Sciences Announce $400 Million Strategic Growth Capital Agreement to Advance duvakitug

• Blackstone Life Sciences will provide $400 million to support development of duvakitug, a human monoclonal antibody targeting TL1A
• Duvakitug is currently in phase 3 clinical studies for ulcerative colitis (UC) and Crohn’s disease (CD)
• Agreement supports Teva’s Pivot to Growth strategy to accelerate its innovative pipeline and drive long-term growth

PARSIPPANY, N.J. and CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and funds managed by Blackstone Life Sciences (“BXLS”) today announced a $400 million strategic funding agreement spread across four years to support the continued clinical development of duvakitug. Additionally, under the terms of the agreement, BXLS will be eligible for regulatory and commercial milestones as well as royalties on duvakitug worldwide sales.

“Today’s announcement highlights how we are turning strategy into action under Pivot to Growth,” said Evan Lippman, Executive Vice President, Business Development, Teva. “By pursuing disciplined, capital-efficient partnerships, we are accelerating pipeline advancement while maintaining financial strength. This is the model we will continue using to build a more innovative, resilient, and growth-oriented Teva.”

Duvakitug is a human monoclonal antibody targeting TL1A, a promising target with the potential for broad therapeutic application across multiple indications. Under a separate and independent agreement announced in 2023, Teva is co-developing and, subject to regulatory approval, will be co-commercializing this asset with Sanofi. Duvakitug is currently in phase 3 clinical studies for the treatment of UC and CD. Both companies recently announced phase 2b duvakitug maintenance data demonstrating clinically meaningful durable efficacy in UC and CD.

“We are excited to partner with Teva and support their innovation priorities as they advance a critical new product to patients who have significant unmet need,” said Dr. Nicholas Galakatos, Global Head of BXLS. “This transaction further demonstrates our focus on partnering with leading biopharmaceutical companies to execute their growth initiatives.”

“Duvakitug has the potential to be a best-in-class therapy in a large and growing space, and the Teva and Sanofi teams are well positioned to develop and commercialize this important medicine,” said Paris Panayiotopoulos, Senior Managing Director, BXLS. “In line with our mission, we are delighted to partner with Teva on their Pivot to Growth strategy and to help bring duvakitug to patients as soon as possible.”

Transaction Terms
Under the agreement, BXLS will provide Teva $400 million to fund ongoing and future development costs for duvakitug, spread over four years. As part of the funding arrangement and subject to the approval of duvakitug by the U.S. Food and Drug Administration (FDA), Teva will pay BXLS a milestone payment. BXLS will also be eligible to receive commercial milestones and low single-digit royalties on duvakitug worldwide sales, subject to customary terms and conditions.

About IBD
IBD is an autoimmune disorder characterized by chronic inflammation of the gastrointestinal (GI) tract. Globally, approximately 4.9 million cases of IBD have been identified, with incidence rising in several regions. The two main types of IBD are UC and CD, which are characterized by repetitive cycles of relapses and remission. Common symptoms of both conditions include persistent diarrhea, rectal bleeding, abdominal pain, loss of appetite, and weight loss.

Prolonged inflammation can lead to damage within the GI tract, including fibrosis, a common complication of IBD characterized by an excessive accumulation of scar tissue in the intestinal wall, which may cause narrowing and obstruction.

Currently, there is no cure for IBD. The goal of current treatment is to induce and maintain remission and prevent flares.

About duvakitug
Duvakitug, a human monoclonal antibody targeting TL1A, is currently in phase 3 clinical studies for the treatment of UC and CD. TL1A signaling is believed to amplify inflammation and drive fibrosis associated with IBD through binding to its receptor, DR3. Duvakitug preferentially inhibits TL1A-DR3 signaling over DcR3 (decoy receptor 3) binding, with the potential to reduce inflammation and fibrosis.

The safety and efficacy of duvakitug have not been reviewed by any regulatory authority.
Under a separate and independent agreement announced in 2023, Teva is co-developing and, subject to regulatory approval, will be co-commercializing this asset with Sanofi.

About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment to bettering health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit www.tevapharm.com.

About Blackstone Life Sciences
Blackstone Life Sciences (BXLS) is a leading private investment platform with capabilities to invest across the life cycle of companies and products within the key life science sectors. By combining scale investments and hands-on operational leadership, BXLS helps bring to market promising new medicines and medical technologies that improve patients’ lives and currently has $15 billion in assets under management.

Teva Cautionary Note Regarding Forward-Looking Statements
This Press Release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as “should,” “expect,” “anticipate,” “estimate,” “target,” “may,” “project,” “guidance,” “intend,” “plan,” “believe” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to: our ability to execute the agreement with Blackstone Life Sciences and to successfully develop and commercialize duvakitug (anti-TL1A; TEV-’574) for the treatment of ulcerative colitis and Crohn’s disease; our ability to successfully compete in the marketplace, including our ability to develop and commercialize additional pharmaceutical products; our ability to successfully execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development, and to execute on our organizational transformation and to achieve expected cost savings; and other factors discussed in our Annual Report on Form 10-K for the year ended December 31, 2025, including in the sections captioned “Risk Factors.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.

Teva Media Inquiries
TevaCommunicationsNorthAmerica@tevapharm.com  

Teva Investor Relations Inquires
TevaIR@Tevapharm.com

Blackstone
David Vitek
(212) 583-5291
David.Vitek@blackstone.com

InterCure Receives Nasdaq Notification Regarding Minimum Bid Requirement




InterCure Receives Nasdaq Notification Regarding Minimum Bid Requirement

NEW YORK and HERZLIYA, Israel, March 03, 2026 (GLOBE NEWSWIRE) — InterCure Ltd. (Nasdaq: INCR) (TASE: INCR) (“InterCure” or the “Company”) today announced that on February 25, 2026 the Company received a written notice (the “Notice”) from the Nasdaq Stock Market LLC indicating that the Company was not in compliance with Nasdaq Listing Rule 5450(a)(2), as the Company’s closing bid price for its ordinary shares, or Ordinary Shares, was below $1.00 per share for the last 30 consecutive business days.

Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has been granted a 180-calendar day compliance period, or until August 24, 2026, to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of the Ordinary Shares must meet or exceed $1.00 per share for at least 10 consecutive business days during the 180-calendar day compliance period.

If the Company is not in compliance by August 24, 2026, the Company expects to be eligible for an additional 180-calendar day compliance period. To qualify for this additional time, the Company will be required to submit a transfer application and meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market, with the exception of the minimum bid price requirement, and to provide written notice of its intention to cure the deficiency during such period.

The Company currently intends monitor the closing price of its Ordinary Shares and to consider effecting a reverse share split, subject to obtaining all required corporate and regulatory approvals, as part of its plan to regain compliance with the minimum bid price requirement, and believes that this measure, together with its ongoing business and strategic initiatives, will support the restoration of compliance within the applicable timeframe. The Company’s Ordinary Shares will continue to be listed and trade on the Nasdaq Global Market during this period, and are unaffected by the receipt of the written notice from Nasdaq.

If the Company does not regain compliance within the allotted compliance period(s), including any extensions that may be granted by Nasdaq, Nasdaq will provide notice that the Company’s Ordinary Shares will be subject to delisting.

This announcement is made in compliance with Nasdaq Listing Rule 5810(b), which requires prompt disclosure of receipt of a deficiency notification.

About InterCure (dba Canndoc)

InterCure (dba Canndoc) (Nasdaq: INCR) (TASE: INCR) is the leading, profitable, and one of the fastest growing cannabis companies outside of North America. Canndoc, a wholly owned subsidiary of InterCure, is Israel’s largest licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products. InterCure leverages its market leading distribution network, best in class international partnerships and a high-margin vertically integrated “seed-to-sale” model to lead the fastest growing cannabis global market outside of North America.

For more information, visit: https://www.intercure.co

Forward-Looking Statements

This press release contains forward-looking statements pursuant to U.S. federal securities laws. Forward-looking statements may include, but are not limited to, statements regarding the Company’s ability to regain compliance with Nasdaq’s minimum bid price requirement, the timing and potential effectiveness of any actions the Company may undertake to cure such deficiency, including the implementation of a reverse share split, and other statements that are not historical facts. These forward-looking statements are often characterized by terminology such as “believes,” “hopes,” “may,” “anticipates,” “should,” “intends,” “plans,” “will,” “expects,” “estimates,” “projects,” “positioned,” “strategy” and similar expressions, and are based on current expectations, assumptions and assessments of the Company’s management in light of its experience and perception of historical trends, current conditions and expected future developments. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. These risks and uncertainties include, among others, the Company’s ability to meet Nasdaq’s continued listing requirements, obtain required approvals for any corporate actions, including a reverse share split, market conditions, and other factors beyond the Company’s control. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in the Company’s most recent Annual Report on Form 20-F and in other filings that the Company has made and may make with the U.S. Securities and Exchange Commission. Except as required by law, the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Company Contact:

InterCure Ltd.
Amos Cohen, Chief Financial Officer
amos@intercure.co 

Oculis Reports Q4 and Full Year 2025 Financial Results and Provides Company Update




Oculis Reports Q4 and Full Year 2025 Financial Results and Provides Company Update

• Significant achievements in 2025, enabling multiple near-term clinical milestones across late-stage portfolio, starting with the forthcoming topline results from DIAMOND Phase 3 trials with OCS-01 eye drops in diabetic macular edema (DME) in Q2 2026
• Key expansion in neuro-ophthalmology with Breakthrough Therapy designation granted to Privosegtor, propelling the PIONEER registrational program in optic neuropathies with a potential U.S. market opportunity of over $7 billion
• Cash, cash equivalents, and short-term investments of $268.7 million as of December 31, 2025, providing cash runway into 2029

ZUG, Switzerland, March 3, 2026 — Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in ophthalmology and neuro-ophthalmology, today announced results for the fourth quarter and full year ended December 31, 2025, and provided an overview of the Company’s progress.

Riad Sherif, M.D., Chief Executive Officer of Oculis, stated “Oculis has delivered a transformative 2025, marked by significant clinical progress across our late-stage portfolio and a strategic expansion into neuro-ophthalmology. The compelling Phase 2 ACUITY results for Privosegtor in optic neuritis led to a pivotal FDA Breakthrough Therapy designation and anchored the launch of our global PIONEER registrational program. We believe Privosegtor holds immense potential as a first-in-class neuroprotective platform for a range of neuro-axonal diseases. 2026 is positioned to be a landmark year for the company with a roadmap featuring three major expected registrational milestones: the DIAMOND-1 and DIAMOND-2 trials readout with OCS-01, a potential first-in-class eye drop in DME, anticipated in Q2, the PREDICT-1 trial results for Licaminlimab with a precision medicine approach in dry eye disease planned in Q4, and the commencement of three registrational trials with Privosegtor as part of the PIONEER program. The operational excellence and significant milestones we achieved in 2025 have uniquely positioned Oculis to drive innovation in areas of high unmet medical need, a potential market opportunity of over $30 billion, with the aim of redefining the standard of care in ophthalmology and neuro-ophthalmology.”

Recent Clinical Highlights and Upcoming Milestones:

Privosegtor:

• Breakthrough Therapy designation recently granted by the FDA for treatment of optic neuritis (ON), a sight-threatening neuro-ophthalmic condition that is often the first clinical manifestation of multiple sclerosis. Designation is supported by the Phase 2 ACUITY trial results, in which Privosegtor + steroid showed substantial improvements in vision and consistent anatomical and biological neuroprotective benefits compared with placebo + steroid. These novel findings reinforced Privosegtor’s potential as a neuroprotective treatment across both neuro-ophthalmic and neurological diseases.
• Following a successful meeting with the FDA in the fall of 2025, Oculis launched the PIONEER program, which includes three pivotal trials in ON and non-arteritic anterior ischemic optic neuropathy (NAION). These two optic neuropathies represent a market opportunity estimated at $7+ billion in the U.S. alone. The first registrational trial in the program, PIONEER-1 in ON, was initiated in Q4 of 2025, with clinical sites activation progressing as planned.

OCS-01:

• Both Phase 3 DIAMOND trials with OCS-01, which aims to be the first eye drop therapy for DME, have enrolled over 800 patients and are nearing completion. Topline results are expected in Q2 2026, and, if positive, a subsequent NDA submission to the FDA is planned for Q4 2026.  
• While the U.S. DME market is currently valued at approximately $3 billion, only a fraction of the 1.8 million people diagnosed^1,2,3 with the disease are successfully managed. This leaves a staggering 1.3 million patients underserved by the current standard of care^1,2,3. OCS-01 is intended to be strategically positioned to capture this ‘lost’ majority by providing a non-invasive, topical eye drop for those requiring early intervention and a versatile option for patients who do not respond to existing injections.

Licaminlimab:

• Oculis recently initiated the first genotype-based registrational trial, PREDICT-1, to drive precision medicine in dry eye disease (DED) with Licaminlimab. In prior Phase 2 studies, Licaminlimab showed a substantially greater treatment effect in patients carrying a specific TNFR1 genotype, with profound improvements ranging from five-fold greater in signs and seven-fold greater in symptoms. Topline results from PREDICT-1 are expected in Q4 2026.
• In the U.S. approximately 10 million patients suffer from moderate to severe DED. Current disease management relies on trial and error, and only 13% of patients experience sustained relief, leading to high discontinuation rates within the first six months, underscoring the strong need for a targeted, effective treatment approach. Licaminlimab has the potential to transform the current treatment paradigm by providing a precision medicine approach with efficacy, rapid onset of action, and a comfort level similar to artificial tears.

Q4 and Full Year 2025 Financial Highlights:

As of December 31, 2025, Oculis held cash, cash equivalents and short-term investments of CHF 213.0 million or $268.7 million, compared to CHF 98.7 million or $109.0 million as of December 31, 2024. The increase in cash, cash equivalents and short-term investments was primarily due to equity financings closed in February and November 2025 for aggregate gross proceeds of $210.0 million (CHF 178.9 million). Research and development expenses were CHF 13.3 million or $16.6 million for the three months ended December 31, 2025, compared to CHF 11.8 million or $13.4 million in the same period in 2024. The increase was primarily due to advancements in clinical development activities of our late-stage portfolio and associated personnel expenses. General and administrative expenses were CHF 7.8 million or $9.7 million for the three months ended December 31, 2025, compared to CHF 5.5 million or $6.3 million in the same period in 2024. The increase was primarily driven by personnel expenses and external professional services costs. Year-to-date net loss was CHF 99.0 million or $119.1 million for the year ended December 31, 2025, compared to CHF 85.8 million or $97.4 million for the same period in 2024. The increase was primarily due to an increase in operating expenses driven by the OCS-01 Phase 3 DIAMOND trials, increased personnel costs and a CHF 7.4 million or $8.9 million increase in foreign exchange revaluation loss, offset by a CHF 3.2 million or $3.9 million decrease in the non-cash fair value adjustment on warrant liabilities resulting from warrant exercises during the year offset by increases in the fair value of outstanding warrants.

Upcoming Events:

Medical Conferences and Industry Events

• COPHy Annual Congress, Mar. 20-21, Krakow, Poland
• NANOS Annual Meeting, Mar. 20-24, Boston, MA, U.S.
• AAN Annual Meeting, Apr. 18-21, Chicago, IL, U.S.
• Eyecelerator, May 1, Denver, CO, U.S.
• ARVO, May 3-7, Denver, CO, U.S.

Investor Conferences

• Leerink Partners Global Healthcare Conference, Mar. 8-11, Miami, FL, U.S.
• Leerink Partners Mountain Meeting, Mar. 22-25, Jackson Hole, WY, U.S.
• Needham Healthcare Conference, Apr. 13-16, Virtual
• Van Lanschot Kempen Life Sciences Conference, Apr. 15-16, Amsterdam, Netherlands

Consolidated Statements of Financial Position (Unaudited)

Consolidated Statements of Loss (Unaudited)

– ENDS-

About Oculis

Oculis is a global biopharmaceutical company (Nasdaq: OCS; XICE: OCS) focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology. Oculis’ highly differentiated late-stage clinical pipeline includes three core product candidates: Privosegtor, a breakthrough neuroprotective candidate in the PIONEER program which consists of studies intended to support registration plans for treatment in optic neuropathies like optic neuritis (ON) and non-arteritic anterior ischemic optic neuropathy (NAION), with potentially broad clinical applications in various other neuro-ophthalmic and neurological diseases; OCS-01, an eye drop in pivotal registration studies, aiming to become the first non-invasive topical treatment for diabetic macular edema (DME); and Licaminlimab, a novel, topical anti-TNFα in registrational trial, which is being developed with a genotype-based approach to drive precision medicine in dry eye disease (DED). Headquartered in Switzerland with operations in the U.S. and Iceland, Oculis is led by an experienced management team with a successful track record and supported by leading international healthcare investors.

For more information, please visit: www.oculis.com

Oculis Contact
Ms. Sylvia Cheung, CFO
sylvia.cheung@oculis.com

Investor Relations
LifeSci Advisors
Corey Davis, Ph.D.
cdavis@lifesciadvisors.com

Media Relations
ICR Healthcare
Amber Fennell / David Daley / Sean Leous
oculis@icrhealthcare.com

Cautionary Statement Regarding Forward Looking Statements

This press release contains forward-looking statements and information. For example, statements regarding the potential benefits of the Company’s product candidates, the initiation, timing, progress and results of current and future clinical trials, Oculis’ research and development programs, regulatory and business strategy; Oculis’ future development plans; the timing or likelihood of regulatory filings and approvals; statements about market opportunity, and the Company’s expected financial position and cash runway, are forward-looking. All forward-looking statements are based on estimates and assumptions that, while considered reasonable by Oculis and its management, are inherently uncertain and are inherently subject to risks, variability, and contingencies, many of which are beyond Oculis’ control. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, assurance, prediction or definitive statement of a fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. All forward-looking statements are subject to risks, uncertainties and other factors that may cause actual results to differ materially from those that we expected and/or those expressed or implied by such forward-looking statements. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of Oculis, including those set forth in the Risk Factors section of Oculis’ annual report on Form 20-F and any other documents filed with the SEC. Copies of these documents are available on the SEC’s website, www.sec.gov. Oculis undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

References:

1. Decision Resources Group: DME – DR Landscape Forecast – Disease Landscape Forecast 2020
2. Iris Registry – Baseline characteristics and demographics of treatment naïve patients at diagnosis (Table S1)
3. Gonzalez 2016 Early and Long-term Responses to VEGF Therapy in DME: Analysis of protocol I data